kw1	kw2	pg	crit_p	edge_weight	inv_edge_weight	R1C1	iteration
nivolumab/therapeutic use	nephritis/chemically induced	0.001934558632970207	0.0036491223311441627	0.020833333333333332	0.8148056077504143	1	2
nivolumab/therapeutic use	glucocorticoids	8.310169974157233e-06	3.204475137636276e-05	0.020833333333333336	0.8148056077504143	1	2
nivolumab/therapeutic use	pruritus/chemically induced	0.001934558632970207	0.0036491223311441627	0.020833333333333336	0.8148056077504143	1	2
nivolumab/therapeutic use	adrenal insufficiency/chemically induced	0.001934558632970207	0.0036491223311441627	0.020833333333333336	0.8148056077504143	1	2
nivolumab/therapeutic use	axitinib/administration & dosage	0.001934558632970207	0.0036491223311441627	0.020833333333333336	0.8148056077504143	1	2
nivolumab/therapeutic use	hypophysitis/chemically induced	0.001934558632970207	0.0036491223311441627	0.020833333333333336	0.8148056077504143	1	2
nivolumab/therapeutic use	angiogenesis inhibitors/therapeutic use	0.001934558632970207	0.0036491223311441627	0.020833333333333336	0.8148056077504143	1	2
nivolumab/therapeutic use	myocarditis/chemically induced	0.001934558632970207	0.0036491223311441627	0.020833333333333336	0.8148056077504143	1	2
nivolumab/therapeutic use	hepatitis autoimmune/etiology	0.001934558632970207	0.0036491223311441627	0.020833333333333336	0.8148056077504143	1	2
nivolumab/therapeutic use	myasthenia gravis/chemically induced	0.001934558632970207	0.0036491223311441627	0.020833333333333336	0.8148056077504143	1	2
nivolumab/therapeutic use	CHI3L1	8.310169974157233e-06	3.204475137636276e-05	0.020833333333333336	0.8148056077504143	1	2
nivolumab/therapeutic use	CXCL8	8.310169974157233e-06	3.204475137636276e-05	0.020833333333333336	0.8148056077504143	1	2
nivolumab/therapeutic use	diabetes mellitus type 1/chemically induced	0.001934558632970207	0.0036491223311441627	0.020833333333333336	0.8148056077504143	1	2
nivolumab/therapeutic use	exanthema/chemically induced	0.001934558632970207	0.0036491223311441627	0.020833333333333336	0.8148056077504143	1	2
nivolumab/therapeutic use	bevacizumab/administration & dosage	0.001934558632970207	0.0036491223311441627	0.020833333333333336	0.8148056077504143	1	2
nivolumab/therapeutic use	arthritis/chemically induced	8.310169974157233e-06	3.204475137636276e-05	0.020833333333333336	0.8148056077504143	1	2
nivolumab/therapeutic use	fatigue/chemically induced	0.001934558632970207	0.0036491223311441627	0.020833333333333336	0.8148056077504143	1	2
immune checkpoint inhibitors	diarrhea	2.1540523135188394e-06	1.2134688235186993e-05	0.09539473684210525	0.5583234571556446	2	2
immune checkpoint inhibitors	colitis ulcerative	5.3053783588552506e-11	5.866794058205013e-10	0.3125	0.8148056077504143	1	2
immune checkpoint inhibitors	ulcer/chemically induced	0.00018983732997190916	0.0004473055463825142	0.3125	0.8148056077504143	1	2
immune checkpoint inhibitors	esophagitis	0.00018983732997190916	0.0004473055463825142	0.3125	0.8148056077504143	1	2
immune checkpoint inhibitors	prednisolone/therapeutic use	0.0013408201055036262	0.0026263486602648347	0.3125	0.8148056077504143	1	2
immune checkpoint inhibitors	carcinoma non-small-cell lung	0.00018983732997190916	0.0004473055463825142	0.3125	0.8148056077504143	1	2
immune checkpoint inhibitors	neoplasms	0.0015045192992561018	0.0029223469660271868	0.36979373622800993	0.5583234571556446	2	2
immune checkpoint inhibitors	colitis/therapy	4.107446643475399e-06	1.6932077879415353e-05	0.3125	0.8148056077504143	1	2
immune checkpoint inhibitors	neoplasm recurrence local/drug therapy	0.004429362111193491	0.007779299842348233	0.3125	0.8148056077504143	1	2
immune checkpoint inhibitors	diarrhea/therapy	0.00018983732997190916	0.0004473055463825142	0.31250000000000006	0.8148056077504143	1	2
immune checkpoint inhibitors	colitis	2.767536030201523e-05	9.166640733947991e-05	0.08891287071487916	0.32151609391373515	3	2
immune checkpoint inhibitors	colitis microscopic/chemically induced	1.4247747426310298e-10	1.5509266729681521e-09	0.09539473684210527	0.5583234571556446	2	2
immune checkpoint inhibitors	immunologic factors	1.4247747426310298e-10	1.5509266729681521e-09	0.09539473684210527	0.5583234571556446	2	2
immune checkpoint inhibitors	neoplasms/therapy	0.00018983732997190916	0.0004473055463825142	0.31250000000000006	0.8148056077504143	1	2
immune checkpoint inhibitors	colitis/chemically induced	1.473762252579558e-05	4.9600050046558395e-05	0.7543638723819438	3.663512830313562e-13	21	2
immune checkpoint inhibitors	endometrial neoplasms/drug therapy	0.004429362111193491	0.007779299842348233	0.31250000000000006	0.8148056077504143	1	2
immune checkpoint inhibitors	antibodies monoclonal humanized	0.004429362111193491	0.007779299842348233	0.31250000000000006	0.8148056077504143	1	2
immune checkpoint inhibitors	crohn disease/drug therapy	4.107446643475399e-06	1.6932077879415353e-05	0.31250000000000006	0.8148056077504143	1	2
immune checkpoint inhibitors	lung neoplasms	0.00018983732997190916	0.0004473055463825142	0.31250000000000006	0.8148056077504143	1	2
immune checkpoint inhibitors	cd8-positive t-lymphocytes	0.00018983732997190916	0.0004473055463825142	0.31250000000000006	0.8148056077504143	1	2
immune checkpoint inhibitors	beclomethasone/adverse effects	0.004429362111193491	0.007779299842348233	0.31250000000000006	0.8148056077504143	1	2
immune checkpoint inhibitors	cytomegalovirus infections/complications	4.107446643475399e-06	1.6932077879415353e-05	0.31250000000000006	0.8148056077504143	1	2
immune checkpoint inhibitors	LTF	0.004429362111193491	0.007779299842348233	0.31250000000000006	0.8148056077504143	1	2
immune checkpoint inhibitors	TNF	0.0003259529145673845	0.0007527531397191532	0.028415453527435616	0.32151609391373515	3	2
nephritis/chemically induced	diabetes mellitus type 1/chemically induced	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
nephritis/chemically induced	exanthema/chemically induced	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
nephritis/chemically induced	bevacizumab/administration & dosage	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
nephritis/chemically induced	pneumonia/chemically induced	0.00465782366002887	0.008058651862136041	0.03125	0.8148056077504143	1	2
nephritis/chemically induced	fatigue/chemically induced	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
nephritis/chemically induced	pruritus/chemically induced	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
nephritis/chemically induced	adrenal insufficiency/chemically induced	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
nephritis/chemically induced	axitinib/administration & dosage	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
nephritis/chemically induced	hypophysitis/chemically induced	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
nephritis/chemically induced	angiogenesis inhibitors/therapeutic use	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
nephritis/chemically induced	myocarditis/chemically induced	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
nephritis/chemically induced	hepatitis autoimmune/etiology	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
nephritis/chemically induced	myasthenia gravis/chemically induced	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
nephritis/chemically induced	immune checkpoint inhibitors/therapeutic use	0.0053848836884015094	0.009179777250211383	0.020833333333333332	0.8148056077504143	1	2
nephritis/chemically induced	ipilimumab/therapeutic use	0.0023623569538192557	0.004323402831420528	0.03125	0.8148056077504143	1	2
nephritis/chemically induced	carcinoma renal cell/drug therapy	0.0007366185030555084	0.0015904263134153022	0.020833333333333336	0.8148056077504143	1	2
gene expression regulation/genetics	cd8-positive t-lymphocytes/cytology	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
gene expression regulation/genetics	inflammation/drug therapy	6.438362607885662e-05	0.00017498280689832294	0.020833333333333332	0.8148056077504143	1	2
gene expression regulation/genetics	myeloid cells/cytology	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
gene expression regulation/genetics	ctla-4 antigen/immunology	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
gene expression regulation/genetics	colitis/drug therapy	0.0002798828857611957	0.0006470743708417025	0.03125	0.8148056077504143	1	2
gene expression regulation/genetics	receptors antigen t-cell/genetics	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
gene expression regulation/genetics	t-lymphocytes regulatory/cytology	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
gene expression regulation/genetics	chemokines/metabolism	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
gene expression regulation/genetics	multigene family	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
gene expression regulation/genetics	melanoma/genetics	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
gene expression regulation/genetics	receptors cxcr6/genetics	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
gene expression regulation/genetics	receptors cxcr3/genetics	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
cd8-positive t-lymphocytes/cytology	melanoma/genetics	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
cd8-positive t-lymphocytes/cytology	receptors cxcr3/genetics	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
cd8-positive t-lymphocytes/cytology	receptors cxcr6/genetics	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
cd8-positive t-lymphocytes/cytology	chemokines/metabolism	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
cd8-positive t-lymphocytes/cytology	multigene family	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
cd8-positive t-lymphocytes/cytology	inflammation/drug therapy	6.438362607885662e-05	0.00017498280689832294	0.020833333333333332	0.8148056077504143	1	2
cd8-positive t-lymphocytes/cytology	myeloid cells/cytology	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
cd8-positive t-lymphocytes/cytology	ctla-4 antigen/immunology	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
cd8-positive t-lymphocytes/cytology	colitis/drug therapy	0.0002798828857611957	0.0006470743708417025	0.03125	0.8148056077504143	1	2
cd8-positive t-lymphocytes/cytology	receptors antigen t-cell/genetics	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
cd8-positive t-lymphocytes/cytology	t-lymphocytes regulatory/cytology	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
glucocorticoids	CHI3L1	6.106226635438361e-15	1.0291946506504979e-13	0.010416666666666668	0.8148056077504143	1	2
glucocorticoids	CXCL8	6.106226635438361e-15	1.0291946506504979e-13	0.010416666666666668	0.8148056077504143	1	2
glucocorticoids	IL17A	5.502966247794561e-06	2.17003763356427e-05	0.020833333333333332	0.8148056077504143	1	2
glucocorticoids	IL6	5.502966247794561e-06	2.17003763356427e-05	0.020833333333333332	0.8148056077504143	1	2
glucocorticoids	arthritis/chemically induced	6.106226635438361e-15	1.0291946506504979e-13	0.010416666666666668	0.8148056077504143	1	2
inflammation/drug therapy	melanoma/genetics	6.438362607885662e-05	0.00017498280689832294	0.020833333333333332	0.8148056077504143	1	2
inflammation/drug therapy	receptors cxcr3/genetics	6.438362607885662e-05	0.00017498280689832294	0.020833333333333332	0.8148056077504143	1	2
inflammation/drug therapy	receptors cxcr6/genetics	6.438362607885662e-05	0.00017498280689832294	0.020833333333333332	0.8148056077504143	1	2
inflammation/drug therapy	myeloid cells/cytology	6.438362607885662e-05	0.00017498280689832294	0.020833333333333336	0.8148056077504143	1	2
inflammation/drug therapy	ctla-4 antigen/immunology	6.438362607885662e-05	0.00017498280689832294	0.020833333333333336	0.8148056077504143	1	2
inflammation/drug therapy	colitis/drug therapy	0.0018041477184351784	0.0034593291114949753	0.0618421052631579	0.8148056077504143	1	2
inflammation/drug therapy	receptors antigen t-cell/genetics	6.438362607885662e-05	0.00017498280689832294	0.020833333333333336	0.8148056077504143	1	2
inflammation/drug therapy	t-lymphocytes regulatory/cytology	6.438362607885662e-05	0.00017498280689832294	0.020833333333333336	0.8148056077504143	1	2
inflammation/drug therapy	chemokines/metabolism	6.438362607885662e-05	0.00017498280689832294	0.020833333333333336	0.8148056077504143	1	2
inflammation/drug therapy	multigene family	6.438362607885662e-05	0.00017498280689832294	0.020833333333333336	0.8148056077504143	1	2
inflammation/drug therapy	beclomethasone/adverse effects	2.338018667558117e-12	2.857578371459921e-11	0.020833333333333336	0.8148056077504143	1	2
pruritus/chemically induced	carcinoma renal cell/drug therapy	0.0007366185030555084	0.0015904263134153022	0.020833333333333336	0.8148056077504143	1	2
pruritus/chemically induced	diabetes mellitus type 1/chemically induced	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
pruritus/chemically induced	exanthema/chemically induced	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
pruritus/chemically induced	bevacizumab/administration & dosage	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
pruritus/chemically induced	pneumonia/chemically induced	0.00465782366002887	0.008058651862136041	0.03125	0.8148056077504143	1	2
pruritus/chemically induced	adrenal insufficiency/chemically induced	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
pruritus/chemically induced	axitinib/administration & dosage	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
pruritus/chemically induced	hypophysitis/chemically induced	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
pruritus/chemically induced	angiogenesis inhibitors/therapeutic use	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
pruritus/chemically induced	myocarditis/chemically induced	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
pruritus/chemically induced	hepatitis autoimmune/etiology	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
pruritus/chemically induced	myasthenia gravis/chemically induced	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
pruritus/chemically induced	immune checkpoint inhibitors/therapeutic use	0.0053848836884015094	0.009179777250211383	0.020833333333333332	0.8148056077504143	1	2
pruritus/chemically induced	ipilimumab/therapeutic use	0.0023623569538192557	0.004323402831420528	0.03125	0.8148056077504143	1	2
pruritus/chemically induced	fatigue/chemically induced	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
diarrhea	neoplasms	1.3927747843922589e-12	2.1247440141458547e-11	0.08201754385964914	0.8148056077504143	1	2
diarrhea	colitis	0.0	0.0	0.0013157894736842107	0.5583234571556446	2	2
diarrhea	recurrence	3.941395586570806e-07	2.340203629526416e-06	0.0618421052631579	0.8148056077504143	1	2
diarrhea	inflammatory bowel diseases	1.865174681370263e-14	3.021872158189031e-13	0.041447368421052636	0.8148056077504143	1	2
neoplasms	infliximab/adverse effects	0.0001653064418433159	0.00039260279937787523	0.15888361088032368	0.8148056077504143	1	2
neoplasms	colitis	1.2192737174787638e-05	4.6332401264193025e-05	0.15888361088032368	0.8148056077504143	1	2
neoplasms	recurrence	0.0003980854743440565	0.0009023846435781758	0.12108062709966406	0.8148056077504143	1	2
neoplasms	inflammatory bowel diseases	7.173081661981939e-08	4.714383859604482e-07	0.08201754385964913	0.8148056077504143	1	2
neoplasms	LTF	0.0	0.0	0.041666666666666664	0.8148056077504143	1	2
immune checkpoint inhibitors/adverse effects	nivolumab/adverse effects	0.0006794212215073259	0.001507420756847464	0.12141258208575266	0.0006491060899161575	9	2
immune checkpoint inhibitors/adverse effects	antineoplastic agents immunological/adverse effects	0.002601484959770528	0.00475271290727308	0.012932342544064696	0.008162767476563658	7	2
immune checkpoint inhibitors/adverse effects	mycophenolic acid	0.00465782366002887	0.008058651862136041	0.5520833333333333	0.8148056077504143	1	2
immune checkpoint inhibitors/adverse effects	gastritis/chemically induced	0.00465782366002887	0.008058651862136041	0.5520833333333333	0.8148056077504143	1	2
immune checkpoint inhibitors/adverse effects	neoplasms/drug therapy	1.9756733141140792e-05	6.585577713713597e-05	0.00567405534370603	3.59998570266185e-05	11	2
immune checkpoint inhibitors/adverse effects	anti-bacterial agents	0.00465782366002887	0.008058651862136041	0.5520833333333333	0.8148056077504143	1	2
immune checkpoint inhibitors/adverse effects	colitis/chemically induced	2.298906887876484e-05	7.650820693729063e-05	0.19576117100009974	0.0	41	2
immune checkpoint inhibitors/adverse effects	adrenal cortex hormones/pharmacology	0.00465782366002887	0.008058651862136041	0.5520833333333333	0.8148056077504143	1	2
myeloid cells/cytology	melanoma/genetics	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
myeloid cells/cytology	receptors cxcr3/genetics	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
myeloid cells/cytology	receptors cxcr6/genetics	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
myeloid cells/cytology	ctla-4 antigen/immunology	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
myeloid cells/cytology	colitis/drug therapy	0.0002798828857611957	0.0006470743708417025	0.03125	0.8148056077504143	1	2
myeloid cells/cytology	receptors antigen t-cell/genetics	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
myeloid cells/cytology	t-lymphocytes regulatory/cytology	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
myeloid cells/cytology	chemokines/metabolism	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
myeloid cells/cytology	multigene family	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
ctla-4 antigen/immunology	melanoma/genetics	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
ctla-4 antigen/immunology	receptors cxcr3/genetics	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
ctla-4 antigen/immunology	receptors cxcr6/genetics	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
ctla-4 antigen/immunology	colitis/drug therapy	0.0002798828857611957	0.0006470743708417025	0.03125	0.8148056077504143	1	2
ctla-4 antigen/immunology	receptors antigen t-cell/genetics	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
ctla-4 antigen/immunology	t-lymphocytes regulatory/cytology	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
ctla-4 antigen/immunology	chemokines/metabolism	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
ctla-4 antigen/immunology	multigene family	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
diabetes mellitus type 1/chemically induced	carcinoma renal cell/drug therapy	0.0007366185030555084	0.0015904263134153022	0.020833333333333336	0.8148056077504143	1	2
diabetes mellitus type 1/chemically induced	exanthema/chemically induced	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
diabetes mellitus type 1/chemically induced	bevacizumab/administration & dosage	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
diabetes mellitus type 1/chemically induced	pneumonia/chemically induced	0.00465782366002887	0.008058651862136041	0.03125	0.8148056077504143	1	2
diabetes mellitus type 1/chemically induced	fatigue/chemically induced	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
diabetes mellitus type 1/chemically induced	adrenal insufficiency/chemically induced	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
diabetes mellitus type 1/chemically induced	axitinib/administration & dosage	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
diabetes mellitus type 1/chemically induced	hypophysitis/chemically induced	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
diabetes mellitus type 1/chemically induced	angiogenesis inhibitors/therapeutic use	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
diabetes mellitus type 1/chemically induced	myocarditis/chemically induced	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
diabetes mellitus type 1/chemically induced	hepatitis autoimmune/etiology	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
diabetes mellitus type 1/chemically induced	myasthenia gravis/chemically induced	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
diabetes mellitus type 1/chemically induced	immune checkpoint inhibitors/therapeutic use	0.0053848836884015094	0.009179777250211383	0.020833333333333332	0.8148056077504143	1	2
diabetes mellitus type 1/chemically induced	ipilimumab/therapeutic use	0.0023623569538192557	0.004323402831420528	0.03125	0.8148056077504143	1	2
adrenal insufficiency/chemically induced	carcinoma renal cell/drug therapy	0.0007366185030555084	0.0015904263134153022	0.020833333333333336	0.8148056077504143	1	2
adrenal insufficiency/chemically induced	exanthema/chemically induced	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
adrenal insufficiency/chemically induced	bevacizumab/administration & dosage	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
adrenal insufficiency/chemically induced	pneumonia/chemically induced	0.00465782366002887	0.008058651862136041	0.03125	0.8148056077504143	1	2
adrenal insufficiency/chemically induced	fatigue/chemically induced	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
adrenal insufficiency/chemically induced	axitinib/administration & dosage	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
adrenal insufficiency/chemically induced	hypophysitis/chemically induced	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
adrenal insufficiency/chemically induced	angiogenesis inhibitors/therapeutic use	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
adrenal insufficiency/chemically induced	myocarditis/chemically induced	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
adrenal insufficiency/chemically induced	hepatitis autoimmune/etiology	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
adrenal insufficiency/chemically induced	myasthenia gravis/chemically induced	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
adrenal insufficiency/chemically induced	immune checkpoint inhibitors/therapeutic use	0.0053848836884015094	0.009179777250211383	0.020833333333333332	0.8148056077504143	1	2
adrenal insufficiency/chemically induced	ipilimumab/therapeutic use	0.0023623569538192557	0.004323402831420528	0.03125	0.8148056077504143	1	2
adrenal gland diseases/diagnostic imaging	pneumonia/diagnostic imaging	1.932526361159148e-10	1.5777265995400858e-09	0.010416666666666668	0.8148056077504143	1	2
adrenal gland diseases/diagnostic imaging	thyroiditis/diagnostic imaging	1.932526361159148e-10	1.5777265995400858e-09	0.010416666666666668	0.8148056077504143	1	2
adrenal gland diseases/diagnostic imaging	myocarditis/diagnostic imaging	1.932526361159148e-10	1.5777265995400858e-09	0.010416666666666668	0.8148056077504143	1	2
adrenal gland diseases/diagnostic imaging	pancreatitis/diagnostic imaging	1.932526361159148e-10	1.5777265995400858e-09	0.010416666666666668	0.8148056077504143	1	2
adrenal gland diseases/diagnostic imaging	neoplasms/diagnostic imaging	4.970686195981955e-09	3.619767996377103e-08	0.020833333333333332	0.8148056077504143	1	2
adrenal gland diseases/diagnostic imaging	sarcoidosis/diagnostic imaging	1.932526361159148e-10	1.5777265995400858e-09	0.010416666666666668	0.8148056077504143	1	2
adrenal gland diseases/diagnostic imaging	hepatitis/diagnostic imaging	1.932526361159148e-10	1.5777265995400858e-09	0.010416666666666668	0.8148056077504143	1	2
adrenal gland diseases/diagnostic imaging	pericarditis/diagnostic imaging	1.932526361159148e-10	1.5777265995400858e-09	0.010416666666666668	0.8148056077504143	1	2
adrenal gland diseases/diagnostic imaging	encephalitis/diagnostic imaging	1.932526361159148e-10	1.5777265995400858e-09	0.010416666666666668	0.8148056077504143	1	2
adrenal gland diseases/diagnostic imaging	colitis/diagnostic imaging	1.932526361159148e-10	1.5777265995400858e-09	0.010416666666666668	0.8148056077504143	1	2
pneumonia/diagnostic imaging	thyroiditis/diagnostic imaging	1.932526361159148e-10	1.5777265995400858e-09	0.010416666666666668	0.8148056077504143	1	2
pneumonia/diagnostic imaging	myocarditis/diagnostic imaging	1.932526361159148e-10	1.5777265995400858e-09	0.010416666666666668	0.8148056077504143	1	2
pneumonia/diagnostic imaging	pancreatitis/diagnostic imaging	1.932526361159148e-10	1.5777265995400858e-09	0.010416666666666668	0.8148056077504143	1	2
pneumonia/diagnostic imaging	neoplasms/diagnostic imaging	4.970686195981955e-09	3.619767996377103e-08	0.020833333333333336	0.8148056077504143	1	2
pneumonia/diagnostic imaging	hepatitis/diagnostic imaging	1.932526361159148e-10	1.5777265995400858e-09	0.010416666666666668	0.8148056077504143	1	2
pneumonia/diagnostic imaging	sarcoidosis/diagnostic imaging	1.932526361159148e-10	1.5777265995400858e-09	0.010416666666666668	0.8148056077504143	1	2
pneumonia/diagnostic imaging	pericarditis/diagnostic imaging	1.932526361159148e-10	1.5777265995400858e-09	0.010416666666666668	0.8148056077504143	1	2
pneumonia/diagnostic imaging	encephalitis/diagnostic imaging	1.932526361159148e-10	1.5777265995400858e-09	0.010416666666666668	0.8148056077504143	1	2
pneumonia/diagnostic imaging	colitis/diagnostic imaging	1.932526361159148e-10	1.5777265995400858e-09	0.010416666666666668	0.8148056077504143	1	2
axitinib/administration & dosage	carcinoma renal cell/drug therapy	0.0007366185030555084	0.0015904263134153022	0.020833333333333336	0.8148056077504143	1	2
axitinib/administration & dosage	exanthema/chemically induced	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
axitinib/administration & dosage	bevacizumab/administration & dosage	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
axitinib/administration & dosage	pneumonia/chemically induced	0.00465782366002887	0.008058651862136041	0.03125	0.8148056077504143	1	2
axitinib/administration & dosage	fatigue/chemically induced	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
axitinib/administration & dosage	hypophysitis/chemically induced	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
axitinib/administration & dosage	angiogenesis inhibitors/therapeutic use	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
axitinib/administration & dosage	myocarditis/chemically induced	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
axitinib/administration & dosage	hepatitis autoimmune/etiology	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
axitinib/administration & dosage	myasthenia gravis/chemically induced	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
axitinib/administration & dosage	immune checkpoint inhibitors/therapeutic use	0.0053848836884015094	0.009179777250211383	0.020833333333333332	0.8148056077504143	1	2
axitinib/administration & dosage	ipilimumab/therapeutic use	0.0023623569538192557	0.004323402831420528	0.03125	0.8148056077504143	1	2
exanthema/chemically induced	carcinoma renal cell/drug therapy	0.0007366185030555084	0.0015904263134153022	0.020833333333333336	0.8148056077504143	1	2
exanthema/chemically induced	bevacizumab/administration & dosage	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
exanthema/chemically induced	pneumonia/chemically induced	0.00465782366002887	0.008058651862136041	0.03125	0.8148056077504143	1	2
exanthema/chemically induced	fatigue/chemically induced	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
exanthema/chemically induced	hypophysitis/chemically induced	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
exanthema/chemically induced	angiogenesis inhibitors/therapeutic use	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
exanthema/chemically induced	myocarditis/chemically induced	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
exanthema/chemically induced	hepatitis autoimmune/etiology	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
exanthema/chemically induced	myasthenia gravis/chemically induced	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
exanthema/chemically induced	immune checkpoint inhibitors/therapeutic use	0.0053848836884015094	0.009179777250211383	0.020833333333333332	0.8148056077504143	1	2
exanthema/chemically induced	ipilimumab/therapeutic use	0.0023623569538192557	0.004323402831420528	0.03125	0.8148056077504143	1	2
bevacizumab/administration & dosage	carcinoma renal cell/drug therapy	0.0007366185030555084	0.0015904263134153022	0.020833333333333336	0.8148056077504143	1	2
bevacizumab/administration & dosage	pneumonia/chemically induced	0.00465782366002887	0.008058651862136041	0.03125	0.8148056077504143	1	2
bevacizumab/administration & dosage	fatigue/chemically induced	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
bevacizumab/administration & dosage	hypophysitis/chemically induced	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
bevacizumab/administration & dosage	angiogenesis inhibitors/therapeutic use	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
bevacizumab/administration & dosage	myocarditis/chemically induced	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
bevacizumab/administration & dosage	hepatitis autoimmune/etiology	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
bevacizumab/administration & dosage	myasthenia gravis/chemically induced	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
bevacizumab/administration & dosage	immune checkpoint inhibitors/therapeutic use	0.0053848836884015094	0.009179777250211383	0.020833333333333332	0.8148056077504143	1	2
bevacizumab/administration & dosage	ipilimumab/therapeutic use	0.0023623569538192557	0.004323402831420528	0.03125	0.8148056077504143	1	2
diarrhea/chemically induced	adrenal cortex hormones/therapeutic use	2.631826862897757e-05	8.730981180089384e-05	0.00041090199761586543	0.1575347199013218	4	2
diarrhea/chemically induced	neoplasms/drug therapy	0.00020435360229709154	0.0004809673747758123	0.019598267251879607	0.06669331816490774	5	2
diarrhea/chemically induced	feces	0.002141516773307428	0.003992658390912154	0.15624999999999997	0.8148056077504143	1	2
diarrhea/chemically induced	biological products/therapeutic use	0.002141516773307428	0.003992658390912154	0.15625000000000003	0.8148056077504143	1	2
diarrhea/chemically induced	beclomethasone/adverse effects	0.002141516773307428	0.003992658390912154	0.15625000000000003	0.8148056077504143	1	2
diarrhea/chemically induced	LTF	0.002141516773307428	0.003992658390912154	0.15625000000000003	0.8148056077504143	1	2
pneumonia/chemically induced	fatigue/chemically induced	0.00465782366002887	0.008058651862136041	0.03125	0.8148056077504143	1	2
pneumonia/chemically induced	antibodies monoclonal humanized/administration & dosage	4.4684711849485304e-05	0.00012903066582211928	0.03125	0.8148056077504143	1	2
pneumonia/chemically induced	carcinoma non-small-cell lung/drug therapy	0.00011151955218924314	0.0002961573876436063	0.06184210526315789	0.8148056077504143	1	2
pneumonia/chemically induced	hypophysitis/chemically induced	0.00465782366002887	0.008058651862136041	0.03125	0.8148056077504143	1	2
pneumonia/chemically induced	angiogenesis inhibitors/therapeutic use	0.00465782366002887	0.008058651862136041	0.03125	0.8148056077504143	1	2
pneumonia/chemically induced	myocarditis/chemically induced	0.00465782366002887	0.008058651862136041	0.03125	0.8148056077504143	1	2
pneumonia/chemically induced	hepatitis autoimmune/etiology	0.00465782366002887	0.008058651862136041	0.03125	0.8148056077504143	1	2
pneumonia/chemically induced	myasthenia gravis/chemically induced	0.00465782366002887	0.008058651862136041	0.03125	0.8148056077504143	1	2
pneumonia/chemically induced	ipilimumab/therapeutic use	8.896086895471278e-06	3.424092377814912e-05	0.001959686450167973	0.5583234571556446	2	2
pneumonia/chemically induced	drugs investigational/administration & dosage	4.4684711849485304e-05	0.00012903066582211928	0.03125	0.8148056077504143	1	2
pneumonia/chemically induced	neoplasms/diagnosis	4.4684711849485304e-05	0.00012903066582211928	0.03125	0.8148056077504143	1	2
fatigue/chemically induced	carcinoma renal cell/drug therapy	0.0007366185030555084	0.0015904263134153022	0.020833333333333336	0.8148056077504143	1	2
fatigue/chemically induced	hypophysitis/chemically induced	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
fatigue/chemically induced	angiogenesis inhibitors/therapeutic use	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
fatigue/chemically induced	myocarditis/chemically induced	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
fatigue/chemically induced	hepatitis autoimmune/etiology	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
fatigue/chemically induced	myasthenia gravis/chemically induced	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
fatigue/chemically induced	immune checkpoint inhibitors/therapeutic use	0.0053848836884015094	0.009179777250211383	0.020833333333333332	0.8148056077504143	1	2
fatigue/chemically induced	ipilimumab/therapeutic use	0.0023623569538192557	0.004323402831420528	0.03125	0.8148056077504143	1	2
colitis	pneumonia	1.5354717497473303e-11	1.744095628789087e-10	0.041666666666666664	0.8148056077504143	1	2
colitis	inflammatory bowel diseases/drug therapy	0.00012348781571447365	0.000296996012477848	0.12108062709966406	0.8148056077504143	1	2
colitis	recurrence	0.001934558632970207	0.0036491223311441627	0.12108062709966406	0.8148056077504143	1	2
colitis	inflammatory bowel diseases	2.1817075618324466e-06	1.2257443022123155e-05	0.08201754385964913	0.8148056077504143	1	2
colitis	ligands	1.5354717497473303e-11	1.744095628789087e-10	0.041666666666666664	0.8148056077504143	1	2
colitis	CTLA4	0.0028432781408095353	0.005180864267037427	0.07497110139796988	0.5583234571556446	2	2
colitis/chemically induced	nivolumab/adverse effects	0.0027818840255287025	0.005077849443978155	0.31349064396220855	0.0001593288589043032	10	2
colitis/chemically induced	neoplasms/drug therapy	0.0010888200139059778	0.0022844758685566496	0.1070948700828539	3.59998570266185e-05	11	2
colitis/chemically induced	ipilimumab/adverse effects	0.00044801279542339145	0.0010122667485782575	0.05015916554474881	0.0006491060899161575	9	2
hypophysitis/chemically induced	carcinoma renal cell/drug therapy	0.0007366185030555084	0.0015904263134153022	0.020833333333333336	0.8148056077504143	1	2
hypophysitis/chemically induced	angiogenesis inhibitors/therapeutic use	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
hypophysitis/chemically induced	myocarditis/chemically induced	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
hypophysitis/chemically induced	hepatitis autoimmune/etiology	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
hypophysitis/chemically induced	myasthenia gravis/chemically induced	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
hypophysitis/chemically induced	immune checkpoint inhibitors/therapeutic use	0.0053848836884015094	0.009179777250211383	0.020833333333333332	0.8148056077504143	1	2
hypophysitis/chemically induced	ipilimumab/therapeutic use	0.0023623569538192557	0.004323402831420528	0.03125	0.8148056077504143	1	2
colitis/drug therapy	melanoma/genetics	0.0002798828857611957	0.0006470743708417025	0.03125	0.8148056077504143	1	2
colitis/drug therapy	receptors cxcr3/genetics	0.0002798828857611957	0.0006470743708417025	0.03125	0.8148056077504143	1	2
colitis/drug therapy	receptors cxcr6/genetics	0.0002798828857611957	0.0006470743708417025	0.03125	0.8148056077504143	1	2
colitis/drug therapy	diarrhea/therapy	1.1102230246251565e-16	2.495017334910298e-15	0.03125	0.8148056077504143	1	2
colitis/drug therapy	neoplasms/therapy	1.1102230246251565e-16	2.495017334910298e-15	0.03125	0.8148056077504143	1	2
colitis/drug therapy	receptors antigen t-cell/genetics	0.0002798828857611957	0.0006470743708417025	0.03125	0.8148056077504143	1	2
colitis/drug therapy	t-lymphocytes regulatory/cytology	0.0002798828857611957	0.0006470743708417025	0.03125	0.8148056077504143	1	2
colitis/drug therapy	feces/chemistry	0.0018041477184351784	0.0034593291114949753	0.09178331466965287	0.8148056077504143	1	2
colitis/drug therapy	leukocyte l1 antigen complex/analysis	0.0018041477184351784	0.0034593291114949753	0.09178331466965287	0.8148056077504143	1	2
colitis/drug therapy	chemokines/metabolism	0.0002798828857611957	0.0006470743708417025	0.03125	0.8148056077504143	1	2
colitis/drug therapy	multigene family	0.0002798828857611957	0.0006470743708417025	0.03125	0.8148056077504143	1	2
angiogenesis inhibitors/therapeutic use	carcinoma renal cell/drug therapy	0.0007366185030555084	0.0015904263134153022	0.020833333333333336	0.8148056077504143	1	2
angiogenesis inhibitors/therapeutic use	myocarditis/chemically induced	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
angiogenesis inhibitors/therapeutic use	hepatitis autoimmune/etiology	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
angiogenesis inhibitors/therapeutic use	myasthenia gravis/chemically induced	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
angiogenesis inhibitors/therapeutic use	immune checkpoint inhibitors/therapeutic use	0.0053848836884015094	0.009179777250211383	0.020833333333333332	0.8148056077504143	1	2
angiogenesis inhibitors/therapeutic use	ipilimumab/therapeutic use	0.0023623569538192557	0.004323402831420528	0.03125	0.8148056077504143	1	2
recurrence	colitis ulcerative/drug therapy	0.0033898437981384477	0.006128696832274528	0.12108062709966406	0.8148056077504143	1	2
recurrence	feces/chemistry	0.0033898437981384477	0.006128696832274528	0.09178331466965287	0.8148056077504143	1	2
recurrence	inflammatory bowel diseases	0.00012348781571447365	0.000296996012477848	0.06184210526315789	0.8148056077504143	1	2
recurrence	leukocyte l1 antigen complex/analysis	0.0033898437981384477	0.006128696832274528	0.09178331466965287	0.8148056077504143	1	2
recurrence	biomarkers/analysis	1.050197648289064e-06	5.948273942883859e-06	0.001959686450167973	0.5583234571556446	2	2
recurrence	antineoplastic agents/adverse effects	0.000965384237917144	0.0020421589648247276	0.03125	0.8148056077504143	1	2
recurrence	intestinal mucosa/chemistry	0.000965384237917144	0.0020421589648247276	0.03125	0.8148056077504143	1	2
recurrence	leukemia lymphocytic chronic b-cell/drug therapy	0.000965384237917144	0.0020421589648247276	0.03125	0.8148056077504143	1	2
recurrence	class i phosphatidylinositol 3-kinases/antagonists & inhibitors	0.000965384237917144	0.0020421589648247276	0.03125	0.8148056077504143	1	2
recurrence	purines/adverse effects	0.000965384237917144	0.0020421589648247276	0.03125	0.8148056077504143	1	2
recurrence	colon/chemistry	0.000965384237917144	0.0020421589648247276	0.03125	0.8148056077504143	1	2
recurrence	lymphocytosis/chemically induced	0.000965384237917144	0.0020421589648247276	0.03125	0.8148056077504143	1	2
recurrence	protein kinase inhibitors/adverse effects	0.000965384237917144	0.0020421589648247276	0.03125	0.8148056077504143	1	2
recurrence	apoptosis/drug effects	0.000965384237917144	0.0020421589648247276	0.03125	0.8148056077504143	1	2
recurrence	quinazolinones/adverse effects	0.000965384237917144	0.0020421589648247276	0.03125	0.8148056077504143	1	2
recurrence	lymphoma non-hodgkin/drug therapy	0.000965384237917144	0.0020421589648247276	0.03125	0.8148056077504143	1	2
recurrence	PIK3CD	0.000965384237917144	0.0020421589648247276	0.03125	0.8148056077504143	1	2
recurrence	diarrhea/diagnosis	4.070513626164285e-08	2.726722268808768e-07	0.03125	0.8148056077504143	1	2
recurrence	colitis microscopic/diagnosis	4.070513626164285e-08	2.726722268808768e-07	0.03125	0.8148056077504143	1	2
myocarditis/chemically induced	carcinoma renal cell/drug therapy	0.0007366185030555084	0.0015904263134153022	0.020833333333333336	0.8148056077504143	1	2
myocarditis/chemically induced	hepatitis autoimmune/etiology	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
myocarditis/chemically induced	myasthenia gravis/chemically induced	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
myocarditis/chemically induced	immune checkpoint inhibitors/therapeutic use	0.0053848836884015094	0.009179777250211383	0.020833333333333332	0.8148056077504143	1	2
myocarditis/chemically induced	ipilimumab/therapeutic use	0.0023623569538192557	0.004323402831420528	0.03125	0.8148056077504143	1	2
hepatitis autoimmune/etiology	carcinoma renal cell/drug therapy	0.0007366185030555084	0.0015904263134153022	0.020833333333333336	0.8148056077504143	1	2
hepatitis autoimmune/etiology	myasthenia gravis/chemically induced	0.00012348781571447365	0.000296996012477848	0.010416666666666668	0.8148056077504143	1	2
hepatitis autoimmune/etiology	immune checkpoint inhibitors/therapeutic use	0.0053848836884015094	0.009179777250211383	0.020833333333333332	0.8148056077504143	1	2
hepatitis autoimmune/etiology	ipilimumab/therapeutic use	0.0023623569538192557	0.004323402831420528	0.03125	0.8148056077504143	1	2
receptors antigen t-cell/genetics	melanoma/genetics	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
receptors antigen t-cell/genetics	receptors cxcr3/genetics	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
receptors antigen t-cell/genetics	receptors cxcr6/genetics	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
receptors antigen t-cell/genetics	t-lymphocytes regulatory/cytology	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
receptors antigen t-cell/genetics	chemokines/metabolism	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
receptors antigen t-cell/genetics	multigene family	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
myasthenia gravis/chemically induced	carcinoma renal cell/drug therapy	0.0007366185030555084	0.0015904263134153022	0.020833333333333336	0.8148056077504143	1	2
myasthenia gravis/chemically induced	immune checkpoint inhibitors/therapeutic use	0.0053848836884015094	0.009179777250211383	0.020833333333333332	0.8148056077504143	1	2
myasthenia gravis/chemically induced	ipilimumab/therapeutic use	0.0023623569538192557	0.004323402831420528	0.03125	0.8148056077504143	1	2
immune checkpoint inhibitors/therapeutic use	sirolimus/therapeutic use	0.002141516773307428	0.003992658390912154	0.020833333333333332	0.8148056077504143	1	2
immune checkpoint inhibitors/therapeutic use	drug-related side effects and adverse reactions/prevention & control	0.002141516773307428	0.003992658390912154	0.020833333333333332	0.8148056077504143	1	2
immune checkpoint inhibitors/therapeutic use	growth inhibitors/therapeutic use	0.002141516773307428	0.003992658390912154	0.020833333333333332	0.8148056077504143	1	2
immune checkpoint inhibitors/therapeutic use	lymphocytes tumor-infiltrating/immunology	0.002141516773307428	0.003992658390912154	0.020833333333333332	0.8148056077504143	1	2
immune checkpoint inhibitors/therapeutic use	phosphatidylinositol 3-kinases/metabolism	0.002141516773307428	0.003992658390912154	0.020833333333333332	0.8148056077504143	1	2
immune checkpoint inhibitors/therapeutic use	cd8-positive t-lymphocytes/immunology	0.002141516773307428	0.003992658390912154	0.020833333333333336	0.8148056077504143	1	2
immune checkpoint inhibitors/therapeutic use	cytotoxicity immunologic	0.002141516773307428	0.003992658390912154	0.020833333333333336	0.8148056077504143	1	2
immune checkpoint inhibitors/therapeutic use	MTOR	0.002141516773307428	0.003992658390912154	0.020833333333333336	0.8148056077504143	1	2
inflammatory bowel diseases	programmed cell death 1 receptor/metabolism	1.865174681370263e-14	3.021872158189031e-13	0.020833333333333332	0.8148056077504143	1	2
inflammatory bowel diseases	colitis/diagnosis	1.1202451188907503e-09	8.768959919406997e-09	0.041447368421052636	0.8148056077504143	1	2
inflammatory bowel diseases	gastrointestinal tract/metabolism	1.865174681370263e-14	3.021872158189031e-13	0.020833333333333336	0.8148056077504143	1	2
inflammatory bowel diseases	b7-h1 antigen/metabolism	1.865174681370263e-14	3.021872158189031e-13	0.020833333333333336	0.8148056077504143	1	2
inflammatory bowel diseases	immune checkpoint inhibitors/pharmacology	4.4684711849485304e-05	0.00012903066582211928	0.08201754385964913	0.8148056077504143	1	2
t-lymphocytes regulatory/cytology	melanoma/genetics	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
t-lymphocytes regulatory/cytology	receptors cxcr3/genetics	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
t-lymphocytes regulatory/cytology	receptors cxcr6/genetics	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
t-lymphocytes regulatory/cytology	chemokines/metabolism	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
t-lymphocytes regulatory/cytology	multigene family	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
ipilimumab/therapeutic use	carcinoma renal cell/drug therapy	9.857895777454218e-08	6.378638444235082e-07	0.0006578947368421054	0.5583234571556446	2	2
ipilimumab/therapeutic use	inflammatory bowel diseases/drug therapy	0.0023623569538192557	0.004323402831420528	0.09178331466965287	0.8148056077504143	1	2
ipilimumab/therapeutic use	carcinoma non-small-cell lung/drug therapy	3.443948684245246e-05	0.00011389007515937602	0.0618421052631579	0.8148056077504143	1	2
ipilimumab/therapeutic use	proton pump inhibitors/adverse effects	3.387585545411298e-09	2.5559760974402934e-08	0.03125	0.8148056077504143	1	2
chemokines/metabolism	melanoma/genetics	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
chemokines/metabolism	receptors cxcr3/genetics	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
chemokines/metabolism	receptors cxcr6/genetics	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
chemokines/metabolism	multigene family	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
myeloid-derived suppressor cells/metabolism	azoxymethane/adverse effects	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
myeloid-derived suppressor cells/metabolism	phthalazines/administration & dosage	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
myeloid-derived suppressor cells/metabolism	dextran sulfate/adverse effects	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
myeloid-derived suppressor cells/metabolism	colonic neoplasms/drug therapy	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
myeloid-derived suppressor cells/metabolism	cell line tumor	0.0012390207660780694	0.002431505540941939	0.020833333333333332	0.8148056077504143	1	2
myeloid-derived suppressor cells/metabolism	poly(adp-ribose) polymerase inhibitors/administration & dosage	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
myeloid-derived suppressor cells/metabolism	piperazines/administration & dosage	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
myeloid-derived suppressor cells/metabolism	APC	0.0018041477184351784	0.0034593291114949753	0.020833333333333332	0.8148056077504143	1	2
myeloid-derived suppressor cells/metabolism	ARG1	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
myeloid-derived suppressor cells/metabolism	PARP1	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
myeloid-derived suppressor cells/metabolism	TIPARP	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
myeloid-derived suppressor cells/metabolism	drug synergism	0.0012390207660780694	0.002431505540941939	0.020833333333333336	0.8148056077504143	1	2
azoxymethane/adverse effects	drug synergism	0.0012390207660780694	0.002431505540941939	0.020833333333333336	0.8148056077504143	1	2
azoxymethane/adverse effects	phthalazines/administration & dosage	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
azoxymethane/adverse effects	dextran sulfate/adverse effects	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
azoxymethane/adverse effects	colonic neoplasms/drug therapy	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
azoxymethane/adverse effects	cell line tumor	0.0012390207660780694	0.002431505540941939	0.020833333333333332	0.8148056077504143	1	2
azoxymethane/adverse effects	poly(adp-ribose) polymerase inhibitors/administration & dosage	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
azoxymethane/adverse effects	piperazines/administration & dosage	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
azoxymethane/adverse effects	APC	0.0018041477184351784	0.0034593291114949753	0.020833333333333332	0.8148056077504143	1	2
azoxymethane/adverse effects	ARG1	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
azoxymethane/adverse effects	PARP1	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
azoxymethane/adverse effects	TIPARP	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
multigene family	melanoma/genetics	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
multigene family	receptors cxcr3/genetics	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
multigene family	receptors cxcr6/genetics	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
CHI3L1	arthritis/chemically induced	6.106226635438361e-15	1.0291946506504979e-13	0.010416666666666668	0.8148056077504143	1	2
CHI3L1	CXCL8	6.106226635438361e-15	1.0291946506504979e-13	0.010416666666666668	0.8148056077504143	1	2
CHI3L1	IL17A	5.502966247794561e-06	2.17003763356427e-05	0.020833333333333332	0.8148056077504143	1	2
CHI3L1	IL6	5.502966247794561e-06	2.17003763356427e-05	0.020833333333333332	0.8148056077504143	1	2
CXCL8	arthritis/chemically induced	6.106226635438361e-15	1.0291946506504979e-13	0.010416666666666668	0.8148056077504143	1	2
CXCL8	IL17A	5.502966247794561e-06	2.17003763356427e-05	0.020833333333333332	0.8148056077504143	1	2
CXCL8	IL6	5.502966247794561e-06	2.17003763356427e-05	0.020833333333333332	0.8148056077504143	1	2
IL17A	interleukin-17/genetics	0.0011116325159435947	0.0022844758685566496	0.020833333333333332	0.8148056077504143	1	2
IL17A	micrornas/genetics	0.0011116325159435947	0.0022844758685566496	0.020833333333333332	0.8148056077504143	1	2
IL17A	lymphocytes tumor-infiltrating/metabolism	0.0011116325159435947	0.0022844758685566496	0.020833333333333332	0.8148056077504143	1	2
IL17A	arthritis/chemically induced	5.502966247794561e-06	2.17003763356427e-05	0.020833333333333332	0.8148056077504143	1	2
IL17A	t-lymphocytes cytotoxic/immunology	0.0011116325159435947	0.0022844758685566496	0.020833333333333332	0.8148056077504143	1	2
IL17A	gene expression regulation neoplastic	0.0011116325159435947	0.0022844758685566496	0.020833333333333332	0.8148056077504143	1	2
IL17A	tumor microenvironment/drug effects	0.0011116325159435947	0.0022844758685566496	0.020833333333333332	0.8148056077504143	1	2
IL17A	colorectal neoplasms/drug therapy	0.0011116325159435947	0.0022844758685566496	0.020833333333333332	0.8148056077504143	1	2
IL17A	ht29 cells	0.0011116325159435947	0.0022844758685566496	0.020833333333333332	0.8148056077504143	1	2
IL17A	b7-h1 antigen/genetics	0.0011116325159435947	0.0022844758685566496	0.020833333333333332	0.8148056077504143	1	2
IL17A	MIR15B	0.0011116325159435947	0.0022844758685566496	0.020833333333333336	0.8148056077504143	1	2
IL17A	NRF1	0.0011116325159435947	0.0022844758685566496	0.020833333333333336	0.8148056077504143	1	2
immune checkpoint inhibitors/administration & dosage	urothelium/drug effects	0.0005123361954004757	0.0011501424794704558	0.041666666666666664	0.8148056077504143	1	2
immune checkpoint inhibitors/administration & dosage	antibodies monoclonal humanized/administration & dosage	0.0010963664451781874	0.0022844758685566496	0.041666666666666664	0.8148056077504143	1	2
immune checkpoint inhibitors/administration & dosage	neoplasms/diagnosis	0.0010963664451781874	0.0022844758685566496	0.041666666666666664	0.8148056077504143	1	2
immune checkpoint inhibitors/administration & dosage	carcinoma non-small-cell lung/complications	0.0005123361954004757	0.0011501424794704558	0.041666666666666664	0.8148056077504143	1	2
immune checkpoint inhibitors/administration & dosage	infliximab/administration & dosage	0.0005123361954004757	0.0011501424794704558	0.041666666666666664	0.8148056077504143	1	2
immune checkpoint inhibitors/administration & dosage	drugs investigational/administration & dosage	0.0010963664451781874	0.0022844758685566496	0.041666666666666664	0.8148056077504143	1	2
immune checkpoint inhibitors/administration & dosage	APC	0.0013357673030194306	0.0026189058755259004	0.0013157894736842105	0.5583234571556446	2	2
immune checkpoint inhibitors/administration & dosage	CRP	0.0005123361954004757	0.0011501424794704558	0.041666666666666664	0.8148056077504143	1	2
IL6	immune system diseases/drug therapy	0.0011116325159435947	0.0022844758685566496	0.020833333333333332	0.8148056077504143	1	2
IL6	arthritis/chemically induced	5.502966247794561e-06	2.17003763356427e-05	0.020833333333333332	0.8148056077504143	1	2
IL6	gastrointestinal neoplasms/drug therapy	0.0011116325159435947	0.0022844758685566496	0.020833333333333332	0.8148056077504143	1	2
IL6	BTLA	0.0011116325159435947	0.0022844758685566496	0.020833333333333332	0.8148056077504143	1	2
IL6	CD28	0.0011116325159435947	0.0022844758685566496	0.020833333333333332	0.8148056077504143	1	2
IL6	CSF2	0.0011116325159435947	0.0022844758685566496	0.020833333333333332	0.8148056077504143	1	2
IL6	HAVCR2	0.0011116325159435947	0.0022844758685566496	0.020833333333333332	0.8148056077504143	1	2
IL6	IL15	0.0011116325159435947	0.0022844758685566496	0.020833333333333332	0.8148056077504143	1	2
IL6	IL17C	0.0011116325159435947	0.0022844758685566496	0.020833333333333332	0.8148056077504143	1	2
IL6	IL21	0.0011116325159435947	0.0022844758685566496	0.020833333333333332	0.8148056077504143	1	2
IL6	IL22	0.004504747686273292	0.007905056813023661	0.041447368421052636	0.8148056077504143	1	2
IL6	IL4	0.0011116325159435947	0.0022844758685566496	0.020833333333333332	0.8148056077504143	1	2
IL6	LIF	0.0011116325159435947	0.0022844758685566496	0.020833333333333336	0.8148056077504143	1	2
phthalazines/administration & dosage	drug synergism	0.0012390207660780694	0.002431505540941939	0.020833333333333336	0.8148056077504143	1	2
phthalazines/administration & dosage	dextran sulfate/adverse effects	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
phthalazines/administration & dosage	colonic neoplasms/drug therapy	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
phthalazines/administration & dosage	cell line tumor	0.0012390207660780694	0.002431505540941939	0.020833333333333332	0.8148056077504143	1	2
phthalazines/administration & dosage	poly(adp-ribose) polymerase inhibitors/administration & dosage	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
phthalazines/administration & dosage	piperazines/administration & dosage	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
phthalazines/administration & dosage	APC	0.0018041477184351784	0.0034593291114949753	0.020833333333333332	0.8148056077504143	1	2
phthalazines/administration & dosage	ARG1	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
phthalazines/administration & dosage	PARP1	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
phthalazines/administration & dosage	TIPARP	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
dextran sulfate/adverse effects	drug synergism	0.0012390207660780694	0.002431505540941939	0.020833333333333336	0.8148056077504143	1	2
dextran sulfate/adverse effects	colonic neoplasms/drug therapy	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
dextran sulfate/adverse effects	cell line tumor	0.0012390207660780694	0.002431505540941939	0.020833333333333332	0.8148056077504143	1	2
dextran sulfate/adverse effects	poly(adp-ribose) polymerase inhibitors/administration & dosage	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
dextran sulfate/adverse effects	piperazines/administration & dosage	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
dextran sulfate/adverse effects	APC	0.0018041477184351784	0.0034593291114949753	0.020833333333333332	0.8148056077504143	1	2
dextran sulfate/adverse effects	ARG1	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
dextran sulfate/adverse effects	PARP1	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
dextran sulfate/adverse effects	TIPARP	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
carcinoma renal cell/drug therapy	inflammatory bowel diseases/drug therapy	0.0007366185030555084	0.0015904263134153022	0.0618421052631579	0.8148056077504143	1	2
carcinoma renal cell/drug therapy	proton pump inhibitors/adverse effects	6.442513189597321e-11	7.086764508557053e-10	0.020833333333333336	0.8148056077504143	1	2
CTLA4	pneumonia	0.005135561319980275	0.008848576388094621	0.125	0.8148056077504143	1	2
CTLA4	inflammatory bowel diseases/drug therapy	0.0028432781408095353	0.005180864267037427	0.04034154535274355	0.5583234571556446	2	2
CTLA4	drug-related side effects and adverse reactions/diagnosis	0.005135561319980275	0.008848576388094621	0.125	0.8148056077504143	1	2
CTLA4	ligands	0.005135561319980275	0.008848576388094621	0.125	0.8148056077504143	1	2
CTLA4	CD274	0.0008940104939683113	0.0019163917255320725	0.00028177819268363754	0.008162767476563658	7	2
CTLA4	ctla-4 antigen/antagonists & inhibitors	0.0014079973082273822	0.0027446736391799967	0.0015397536394176929	0.32151609391373515	3	2
CTLA4	PDCD1	0.0004655605716644695	0.001050779260020239	5.149541243449557e-07	3.59998570266185e-05	11	2
colonic neoplasms/drug therapy	drug synergism	0.0012390207660780694	0.002431505540941939	0.020833333333333336	0.8148056077504143	1	2
colonic neoplasms/drug therapy	cell line tumor	0.0012390207660780694	0.002431505540941939	0.020833333333333332	0.8148056077504143	1	2
colonic neoplasms/drug therapy	poly(adp-ribose) polymerase inhibitors/administration & dosage	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
colonic neoplasms/drug therapy	piperazines/administration & dosage	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
colonic neoplasms/drug therapy	APC	0.0018041477184351784	0.0034593291114949753	0.020833333333333332	0.8148056077504143	1	2
colonic neoplasms/drug therapy	ARG1	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
colonic neoplasms/drug therapy	PARP1	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
colonic neoplasms/drug therapy	TIPARP	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
hashimoto disease/chemically induced	nivolumab/adverse effects	0.0023623569538192557	0.004323402831420528	0.125	0.8148056077504143	1	2
hashimoto disease/chemically induced	squamous cell carcinoma of head and neck/drug therapy	6.106226635438361e-15	1.0291946506504979e-13	0.010416666666666668	0.8148056077504143	1	2
hashimoto disease/chemically induced	tongue neoplasms/drug therapy	6.106226635438361e-15	1.0291946506504979e-13	0.010416666666666668	0.8148056077504143	1	2
hashimoto disease/chemically induced	paclitaxel/therapeutic use	6.106226635438361e-15	1.0291946506504979e-13	0.010416666666666668	0.8148056077504143	1	2
hashimoto disease/chemically induced	colitis ulcerative/chemically induced	6.106226635438361e-15	1.0291946506504979e-13	0.010416666666666668	0.8148056077504143	1	2
hashimoto disease/chemically induced	antineoplastic agents immunological/adverse effects	0.0005488898077088411	0.0012243113106846083	0.07291666666666667	0.8148056077504143	1	2
hashimoto disease/chemically induced	SNCA	7.336218259546001e-07	4.1778463657905015e-06	0.03125	0.8148056077504143	1	2
nivolumab/adverse effects	prednisolone/therapeutic use	3.351094341796923e-06	1.463145096787808e-05	0.125	0.8148056077504143	1	2
nivolumab/adverse effects	lung neoplasms/drug therapy	0.0023623569538192557	0.004323402831420528	0.23552631578947367	0.8148056077504143	1	2
nivolumab/adverse effects	protein kinase inhibitors/therapeutic use	0.0005123361954004757	0.0011501424794704558	0.12500000000000003	0.8148056077504143	1	2
nivolumab/adverse effects	squamous cell carcinoma of head and neck/drug therapy	0.0023623569538192557	0.004323402831420528	0.12500000000000003	0.8148056077504143	1	2
nivolumab/adverse effects	tongue neoplasms/drug therapy	0.0023623569538192557	0.004323402831420528	0.12500000000000003	0.8148056077504143	1	2
nivolumab/adverse effects	carcinoma non-small-cell lung/drug therapy	0.004063911932208342	0.007167574631489817	0.23552631578947367	0.8148056077504143	1	2
nivolumab/adverse effects	ipilimumab/adverse effects	0.0	0.0	2.161680263935751e-06	0.008162767476563658	7	2
nivolumab/adverse effects	paclitaxel/therapeutic use	0.0023623569538192557	0.004323402831420528	0.12500000000000003	0.8148056077504143	1	2
nivolumab/adverse effects	oropharyngeal neoplasms/drug therapy	3.351094341796923e-06	1.463145096787808e-05	0.12500000000000003	0.8148056077504143	1	2
nivolumab/adverse effects	disease susceptibility	3.351094341796923e-06	1.463145096787808e-05	0.12500000000000003	0.8148056077504143	1	2
nivolumab/adverse effects	colitis ulcerative/chemically induced	0.0023623569538192557	0.004323402831420528	0.12500000000000003	0.8148056077504143	1	2
nivolumab/adverse effects	drug-related side effects and adverse reactions/diagnosis	0.0001653064418433159	0.00039260279937787523	0.12500000000000003	0.8148056077504143	1	2
nivolumab/adverse effects	postoperative complications	3.351094341796923e-06	1.463145096787808e-05	0.12500000000000003	0.8148056077504143	1	2
PDCD1	CD274	0.00016333607624730018	0.00038880683298047534	1.012304913553398e-07	1.4673563945084996e-06	13	2
PDCD1	inflammatory bowel diseases/complications	0.0047409327580072436	0.0081956571250911	0.06578947368421052	0.5583234571556446	2	2
sirolimus/therapeutic use	drug-related side effects and adverse reactions/prevention & control	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
sirolimus/therapeutic use	growth inhibitors/therapeutic use	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
sirolimus/therapeutic use	phosphatidylinositol 3-kinases/metabolism	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
sirolimus/therapeutic use	lymphocytes tumor-infiltrating/immunology	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
sirolimus/therapeutic use	colitis/etiology	0.00014324390160591616	0.0003413680209308606	0.020833333333333332	0.8148056077504143	1	2
sirolimus/therapeutic use	cell line tumor	0.0012390207660780694	0.002431505540941939	0.020833333333333332	0.8148056077504143	1	2
sirolimus/therapeutic use	cd8-positive t-lymphocytes/immunology	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
sirolimus/therapeutic use	cytotoxicity immunologic	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
sirolimus/therapeutic use	MTOR	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
sirolimus/therapeutic use	drug synergism	0.0012390207660780694	0.002431505540941939	0.020833333333333336	0.8148056077504143	1	2
drug-related side effects and adverse reactions/prevention & control	drug synergism	0.0012390207660780694	0.002431505540941939	0.020833333333333336	0.8148056077504143	1	2
drug-related side effects and adverse reactions/prevention & control	growth inhibitors/therapeutic use	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
drug-related side effects and adverse reactions/prevention & control	phosphatidylinositol 3-kinases/metabolism	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
drug-related side effects and adverse reactions/prevention & control	lymphocytes tumor-infiltrating/immunology	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
drug-related side effects and adverse reactions/prevention & control	colitis/etiology	0.00014324390160591616	0.0003413680209308606	0.020833333333333332	0.8148056077504143	1	2
drug-related side effects and adverse reactions/prevention & control	cell line tumor	0.0012390207660780694	0.002431505540941939	0.020833333333333332	0.8148056077504143	1	2
drug-related side effects and adverse reactions/prevention & control	cd8-positive t-lymphocytes/immunology	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
drug-related side effects and adverse reactions/prevention & control	cytotoxicity immunologic	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
drug-related side effects and adverse reactions/prevention & control	MTOR	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
cell line tumor	drug synergism	9.365649501713591e-06	3.5981999004745234e-05	0.0002192982456140351	0.5583234571556446	2	2
cell line tumor	growth inhibitors/therapeutic use	0.0012390207660780694	0.002431505540941939	0.020833333333333332	0.8148056077504143	1	2
cell line tumor	lymphocytes tumor-infiltrating/immunology	0.0012390207660780694	0.002431505540941939	0.020833333333333332	0.8148056077504143	1	2
cell line tumor	phosphatidylinositol 3-kinases/metabolism	0.0012390207660780694	0.002431505540941939	0.020833333333333332	0.8148056077504143	1	2
cell line tumor	poly(adp-ribose) polymerase inhibitors/administration & dosage	0.0012390207660780694	0.002431505540941939	0.020833333333333336	0.8148056077504143	1	2
cell line tumor	cd8-positive t-lymphocytes/immunology	0.0012390207660780694	0.002431505540941939	0.020833333333333336	0.8148056077504143	1	2
cell line tumor	piperazines/administration & dosage	0.0012390207660780694	0.002431505540941939	0.020833333333333336	0.8148056077504143	1	2
cell line tumor	cytotoxicity immunologic	0.0012390207660780694	0.002431505540941939	0.020833333333333336	0.8148056077504143	1	2
cell line tumor	ARG1	0.0012390207660780694	0.002431505540941939	0.020833333333333336	0.8148056077504143	1	2
cell line tumor	MTOR	0.0012390207660780694	0.002431505540941939	0.020833333333333336	0.8148056077504143	1	2
cell line tumor	PARP1	0.0012390207660780694	0.002431505540941939	0.020833333333333336	0.8148056077504143	1	2
cell line tumor	TIPARP	0.0012390207660780694	0.002431505540941939	0.020833333333333336	0.8148056077504143	1	2
poly(adp-ribose) polymerase inhibitors/administration & dosage	drug synergism	0.0012390207660780694	0.002431505540941939	0.020833333333333336	0.8148056077504143	1	2
poly(adp-ribose) polymerase inhibitors/administration & dosage	piperazines/administration & dosage	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
poly(adp-ribose) polymerase inhibitors/administration & dosage	APC	0.0018041477184351784	0.0034593291114949753	0.020833333333333332	0.8148056077504143	1	2
poly(adp-ribose) polymerase inhibitors/administration & dosage	ARG1	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
poly(adp-ribose) polymerase inhibitors/administration & dosage	PARP1	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
poly(adp-ribose) polymerase inhibitors/administration & dosage	TIPARP	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
squamous cell carcinoma of head and neck/drug therapy	tongue neoplasms/drug therapy	6.106226635438361e-15	1.0291946506504979e-13	0.010416666666666668	0.8148056077504143	1	2
squamous cell carcinoma of head and neck/drug therapy	paclitaxel/therapeutic use	6.106226635438361e-15	1.0291946506504979e-13	0.010416666666666668	0.8148056077504143	1	2
squamous cell carcinoma of head and neck/drug therapy	colitis ulcerative/chemically induced	6.106226635438361e-15	1.0291946506504979e-13	0.010416666666666668	0.8148056077504143	1	2
squamous cell carcinoma of head and neck/drug therapy	antineoplastic agents immunological/adverse effects	0.0005488898077088411	0.0012243113106846083	0.07291666666666667	0.8148056077504143	1	2
squamous cell carcinoma of head and neck/drug therapy	SNCA	7.336218259546001e-07	4.1778463657905015e-06	0.03125	0.8148056077504143	1	2
tongue neoplasms/drug therapy	paclitaxel/therapeutic use	6.106226635438361e-15	1.0291946506504979e-13	0.010416666666666668	0.8148056077504143	1	2
tongue neoplasms/drug therapy	colitis ulcerative/chemically induced	6.106226635438361e-15	1.0291946506504979e-13	0.010416666666666668	0.8148056077504143	1	2
tongue neoplasms/drug therapy	antineoplastic agents immunological/adverse effects	0.0005488898077088411	0.0012243113106846083	0.07291666666666667	0.8148056077504143	1	2
tongue neoplasms/drug therapy	SNCA	7.336218259546001e-07	4.1778463657905015e-06	0.03125	0.8148056077504143	1	2
inflammatory bowel diseases/drug therapy	proton pump inhibitors/adverse effects	1.3955503419538218e-13	2.243615549756529e-12	0.03125	0.8148056077504143	1	2
inflammatory bowel diseases/drug therapy	CD4	0.00012348781571447365	0.000296996012477848	0.06184210526315789	0.8148056077504143	1	2
inflammatory bowel diseases/drug therapy	CD68	0.00012348781571447365	0.000296996012477848	0.06184210526315789	0.8148056077504143	1	2
ulcer/chemically induced	esophagitis	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
piperazines/administration & dosage	drug synergism	0.0012390207660780694	0.002431505540941939	0.020833333333333336	0.8148056077504143	1	2
piperazines/administration & dosage	APC	0.0018041477184351784	0.0034593291114949753	0.020833333333333332	0.8148056077504143	1	2
piperazines/administration & dosage	ARG1	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
piperazines/administration & dosage	PARP1	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
piperazines/administration & dosage	TIPARP	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
APC	interleukin-17/genetics	0.003518649881307012	0.006237470951595977	0.020833333333333332	0.8148056077504143	1	2
APC	micrornas/genetics	0.003518649881307012	0.006237470951595977	0.020833333333333332	0.8148056077504143	1	2
APC	lymphocytes tumor-infiltrating/metabolism	0.003518649881307012	0.006237470951595977	0.020833333333333332	0.8148056077504143	1	2
APC	gene expression regulation neoplastic	0.003518649881307012	0.006237470951595977	0.020833333333333332	0.8148056077504143	1	2
APC	tumor microenvironment/drug effects	0.003518649881307012	0.006237470951595977	0.020833333333333332	0.8148056077504143	1	2
APC	colorectal neoplasms/drug therapy	0.003518649881307012	0.006237470951595977	0.020833333333333332	0.8148056077504143	1	2
APC	ht29 cells	0.003518649881307012	0.006237470951595977	0.020833333333333332	0.8148056077504143	1	2
APC	t-lymphocytes cytotoxic/immunology	0.003518649881307012	0.006237470951595977	0.020833333333333332	0.8148056077504143	1	2
APC	b7-h1 antigen/genetics	0.003518649881307012	0.006237470951595977	0.020833333333333332	0.8148056077504143	1	2
APC	ARG1	0.0018041477184351784	0.0034593291114949753	0.020833333333333336	0.8148056077504143	1	2
APC	MIR15B	0.003518649881307012	0.006237470951595977	0.020833333333333336	0.8148056077504143	1	2
APC	NRF1	0.003518649881307012	0.006237470951595977	0.020833333333333336	0.8148056077504143	1	2
APC	PARP1	0.0018041477184351784	0.0034593291114949753	0.020833333333333336	0.8148056077504143	1	2
APC	TIPARP	0.0018041477184351784	0.0034593291114949753	0.020833333333333336	0.8148056077504143	1	2
ARG1	drug synergism	0.0012390207660780694	0.002431505540941939	0.020833333333333336	0.8148056077504143	1	2
ARG1	PARP1	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
ARG1	TIPARP	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
intestinal mucosa/diagnostic imaging	colon/diagnostic imaging	2.338018667558117e-12	2.857578371459921e-11	0.010416666666666668	0.8148056077504143	1	2
intestinal mucosa/diagnostic imaging	drug resistance/immunology	2.338018667558117e-12	2.857578371459921e-11	0.010416666666666668	0.8148056077504143	1	2
intestinal mucosa/diagnostic imaging	skin neoplasms/drug therapy	1.9921871419192883e-07	1.2033731579801481e-06	0.020833333333333332	0.8148056077504143	1	2
intestinal mucosa/diagnostic imaging	infliximab/adverse effects	7.267737133442864e-06	2.8233402618765034e-05	0.041666666666666664	0.8148056077504143	1	2
intestinal mucosa/diagnostic imaging	glucocorticoids/pharmacology	2.338018667558117e-12	2.857578371459921e-11	0.010416666666666668	0.8148056077504143	1	2
intestinal mucosa/diagnostic imaging	melanoma/drug therapy	8.546906613060568e-05	0.00022842755525954715	0.05208333333333334	0.8148056077504143	1	2
intestinal mucosa/diagnostic imaging	immunosuppressive agents/pharmacology	2.338018667558117e-12	2.857578371459921e-11	0.010416666666666668	0.8148056077504143	1	2
intestinal mucosa/diagnostic imaging	mucositis/chemically induced	2.338018667558117e-12	2.857578371459921e-11	0.010416666666666668	0.8148056077504143	1	2
colon/diagnostic imaging	drug resistance/immunology	2.338018667558117e-12	2.857578371459921e-11	0.010416666666666668	0.8148056077504143	1	2
colon/diagnostic imaging	skin neoplasms/drug therapy	1.9921871419192883e-07	1.2033731579801481e-06	0.020833333333333332	0.8148056077504143	1	2
colon/diagnostic imaging	infliximab/adverse effects	7.267737133442864e-06	2.8233402618765034e-05	0.041666666666666664	0.8148056077504143	1	2
colon/diagnostic imaging	glucocorticoids/pharmacology	2.338018667558117e-12	2.857578371459921e-11	0.010416666666666668	0.8148056077504143	1	2
colon/diagnostic imaging	melanoma/drug therapy	8.546906613060568e-05	0.00022842755525954715	0.05208333333333334	0.8148056077504143	1	2
colon/diagnostic imaging	immunosuppressive agents/pharmacology	2.338018667558117e-12	2.857578371459921e-11	0.010416666666666668	0.8148056077504143	1	2
colon/diagnostic imaging	mucositis/chemically induced	2.338018667558117e-12	2.857578371459921e-11	0.010416666666666668	0.8148056077504143	1	2
drug resistance/immunology	skin neoplasms/drug therapy	1.9921871419192883e-07	1.2033731579801481e-06	0.020833333333333332	0.8148056077504143	1	2
drug resistance/immunology	infliximab/adverse effects	7.267737133442864e-06	2.8233402618765034e-05	0.041666666666666664	0.8148056077504143	1	2
drug resistance/immunology	glucocorticoids/pharmacology	2.338018667558117e-12	2.857578371459921e-11	0.010416666666666668	0.8148056077504143	1	2
drug resistance/immunology	melanoma/drug therapy	8.546906613060568e-05	0.00022842755525954715	0.05208333333333334	0.8148056077504143	1	2
drug resistance/immunology	immunosuppressive agents/pharmacology	2.338018667558117e-12	2.857578371459921e-11	0.010416666666666668	0.8148056077504143	1	2
drug resistance/immunology	mucositis/chemically induced	2.338018667558117e-12	2.857578371459921e-11	0.010416666666666668	0.8148056077504143	1	2
paclitaxel/therapeutic use	colitis ulcerative/chemically induced	6.106226635438361e-15	1.0291946506504979e-13	0.010416666666666668	0.8148056077504143	1	2
paclitaxel/therapeutic use	antineoplastic agents immunological/adverse effects	0.0005488898077088411	0.0012243113106846083	0.07291666666666667	0.8148056077504143	1	2
paclitaxel/therapeutic use	SNCA	7.336218259546001e-07	4.1778463657905015e-06	0.03125	0.8148056077504143	1	2
growth inhibitors/therapeutic use	drug synergism	0.0012390207660780694	0.002431505540941939	0.020833333333333336	0.8148056077504143	1	2
growth inhibitors/therapeutic use	phosphatidylinositol 3-kinases/metabolism	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
growth inhibitors/therapeutic use	lymphocytes tumor-infiltrating/immunology	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
growth inhibitors/therapeutic use	colitis/etiology	0.00014324390160591616	0.0003413680209308606	0.020833333333333332	0.8148056077504143	1	2
growth inhibitors/therapeutic use	cd8-positive t-lymphocytes/immunology	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
growth inhibitors/therapeutic use	cytotoxicity immunologic	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
growth inhibitors/therapeutic use	MTOR	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
PARP1	drug synergism	0.0012390207660780694	0.002431505540941939	0.020833333333333336	0.8148056077504143	1	2
PARP1	TIPARP	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
colitis ulcerative/chemically induced	antineoplastic agents immunological/adverse effects	0.0005488898077088411	0.0012243113106846083	0.07291666666666667	0.8148056077504143	1	2
colitis ulcerative/chemically induced	SNCA	7.336218259546001e-07	4.1778463657905015e-06	0.03125	0.8148056077504143	1	2
TIPARP	drug synergism	0.0012390207660780694	0.002431505540941939	0.020833333333333336	0.8148056077504143	1	2
skin neoplasms/drug therapy	infliximab/adverse effects	0.000965384237917144	0.0020421589648247276	0.08201754385964914	0.8148056077504143	1	2
skin neoplasms/drug therapy	tumor necrosis factor inhibitors	5.6286374450209564e-09	4.0846709236436805e-08	0.020833333333333336	0.8148056077504143	1	2
skin neoplasms/drug therapy	glucocorticoids/pharmacology	1.9921871419192883e-07	1.2033731579801481e-06	0.020833333333333336	0.8148056077504143	1	2
skin neoplasms/drug therapy	melanoma/drug therapy	8.498183490246447e-09	6.145745153846046e-08	0.002192982456140351	0.5583234571556446	2	2
skin neoplasms/drug therapy	immunosuppressive agents/pharmacology	1.9921871419192883e-07	1.2033731579801481e-06	0.020833333333333336	0.8148056077504143	1	2
skin neoplasms/drug therapy	mucositis/chemically induced	1.9921871419192883e-07	1.2033731579801481e-06	0.020833333333333336	0.8148056077504143	1	2
skin neoplasms/drug therapy	SNCA	0.0005488898077088411	0.0012243113106846083	0.0618421052631579	0.8148056077504143	1	2
skin neoplasms/drug therapy	TNF	0.0007366185030555084	0.0015904263134153022	0.0618421052631579	0.8148056077504143	1	2
infliximab/adverse effects	antibodies monoclonal humanized/therapeutic use	8.120171202108395e-13	1.247879250912246e-11	0.041666666666666664	0.8148056077504143	1	2
infliximab/adverse effects	steroids/adverse effects	8.120171202108395e-13	1.247879250912246e-11	0.041666666666666664	0.8148056077504143	1	2
infliximab/adverse effects	glucocorticoids/pharmacology	7.267737133442864e-06	2.8233402618765034e-05	0.041666666666666664	0.8148056077504143	1	2
infliximab/adverse effects	melanoma/drug therapy	8.428845669206098e-07	4.787034632782811e-06	0.012602499729075609	0.5583234571556446	2	2
infliximab/adverse effects	immunosuppressive agents/pharmacology	7.267737133442864e-06	2.8233402618765034e-05	0.041666666666666664	0.8148056077504143	1	2
infliximab/adverse effects	drug-related side effects and adverse reactions	9.025969544573798e-05	0.00024092306958057775	0.08201754385964913	0.8148056077504143	1	2
infliximab/adverse effects	mucositis/chemically induced	7.267737133442864e-06	2.8233402618765034e-05	0.041666666666666664	0.8148056077504143	1	2
infliximab/adverse effects	LTF	1.621400791407268e-10	1.5777265995400858e-09	0.041666666666666664	0.8148056077504143	1	2
infliximab/adverse effects	TNF	0.003785246270538556	0.006698700004594057	0.12108062709966406	0.8148056077504143	1	2
programmed cell death 1 receptor/antagonists & inhibitors	colitis/epidemiology	0.001679672935723131	0.0032595324379399667	0.08333333333333333	0.8148056077504143	1	2
programmed cell death 1 receptor/antagonists & inhibitors	b7-h1 antigen/antagonists & inhibitors	0.001406345716636337	0.0027446736391799967	0.01763717805151176	0.5583234571556446	2	2
programmed cell death 1 receptor/antagonists & inhibitors	ctla-4 antigen/antagonists & inhibitors	0.00023408825538462352	0.0005503312190707122	0.0003919372900335946	0.32151609391373515	3	2
programmed cell death 1 receptor/antagonists & inhibitors	antineoplastic agents immunological/adverse effects	0.002929326178977343	0.005333006719566765	0.011618589114352483	0.32151609391373515	3	2
phosphatidylinositol 3-kinases/metabolism	drug synergism	0.0012390207660780694	0.002431505540941939	0.020833333333333336	0.8148056077504143	1	2
phosphatidylinositol 3-kinases/metabolism	lymphocytes tumor-infiltrating/immunology	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
phosphatidylinositol 3-kinases/metabolism	colitis/etiology	0.00014324390160591616	0.0003413680209308606	0.020833333333333332	0.8148056077504143	1	2
phosphatidylinositol 3-kinases/metabolism	cd8-positive t-lymphocytes/immunology	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
phosphatidylinositol 3-kinases/metabolism	cytotoxicity immunologic	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
phosphatidylinositol 3-kinases/metabolism	MTOR	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
antineoplastic agents immunological/therapeutic use	glucocorticoids/therapeutic use	0.00033518505195040404	0.0007698206138201587	0.03125	0.8148056077504143	1	2
antineoplastic agents immunological/therapeutic use	disease progression	0.00033518505195040404	0.0007698206138201587	0.03125	0.8148056077504143	1	2
antineoplastic agents immunological/therapeutic use	abdominal pain/chemically induced	0.00033518505195040404	0.0007698206138201587	0.03125	0.8148056077504143	1	2
antineoplastic agents immunological/therapeutic use	gastritis/complications	0.00033518505195040404	0.0007698206138201587	0.03125	0.8148056077504143	1	2
antineoplastic agents immunological/therapeutic use	enterocolitis/chemically induced	0.0020710029803291397	0.0039029722532803444	0.06184210526315789	0.8148056077504143	1	2
lymphocytes tumor-infiltrating/immunology	drug synergism	0.0012390207660780694	0.002431505540941939	0.020833333333333336	0.8148056077504143	1	2
lymphocytes tumor-infiltrating/immunology	colitis/etiology	0.00014324390160591616	0.0003413680209308606	0.020833333333333332	0.8148056077504143	1	2
lymphocytes tumor-infiltrating/immunology	cd8-positive t-lymphocytes/immunology	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
lymphocytes tumor-infiltrating/immunology	cytotoxicity immunologic	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
lymphocytes tumor-infiltrating/immunology	MTOR	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
antineoplastic agents immunological/adverse effects	vitamin d	1.439032364380921e-07	9.08633728566805e-07	0.07291666666666667	0.8148056077504143	1	2
antineoplastic agents immunological/adverse effects	host microbial interactions/drug effects	8.087693600788981e-05	0.00021867114651551061	0.07291666666666667	0.8148056077504143	1	2
antineoplastic agents immunological/adverse effects	metabolome/drug effects	8.087693600788981e-05	0.00021867114651551061	0.07291666666666667	0.8148056077504143	1	2
antineoplastic agents immunological/adverse effects	lymphocytes/drug effects	0.0018904226520841672	0.003611502141550191	0.07291666666666667	0.8148056077504143	1	2
antineoplastic agents immunological/adverse effects	dysbiosis/etiology	8.087693600788981e-05	0.00021867114651551061	0.07291666666666667	0.8148056077504143	1	2
antineoplastic agents immunological/adverse effects	vitamin d/administration & dosage	0.0018904226520841672	0.003611502141550191	0.07291666666666667	0.8148056077504143	1	2
antineoplastic agents immunological/adverse effects	cytomegalovirus infections/diagnosis	1.1202451188907503e-09	8.768959919406997e-09	0.07291666666666667	0.8148056077504143	1	2
antineoplastic agents immunological/adverse effects	anti-bacterial agents/pharmacology	8.087693600788981e-05	0.00021867114651551061	0.07291666666666667	0.8148056077504143	1	2
antineoplastic agents immunological/adverse effects	neutrophils/drug effects	0.0018904226520841672	0.003611502141550191	0.07291666666666667	0.8148056077504143	1	2
antineoplastic agents immunological/adverse effects	ctla-4 antigen/antagonists & inhibitors	0.0006196793094797037	0.0013763334291313292	0.013325867861142216	0.5583234571556446	2	2
antineoplastic agents immunological/adverse effects	antibodies monoclonal/adverse effects	0.0018904226520841672	0.003611502141550191	0.07291666666666667	0.8148056077504143	1	2
colitis/etiology	host microbial interactions/drug effects	1.7873572066839927e-08	1.2662971396506933e-07	0.020833333333333332	0.8148056077504143	1	2
colitis/etiology	metabolome/drug effects	1.7873572066839927e-08	1.2662971396506933e-07	0.020833333333333332	0.8148056077504143	1	2
colitis/etiology	dysbiosis/etiology	1.7873572066839927e-08	1.2662971396506933e-07	0.020833333333333332	0.8148056077504143	1	2
colitis/etiology	neoplasms/complications	0.0007837691687692105	0.001681804479186499	0.06184210526315789	0.8148056077504143	1	2
colitis/etiology	cd8-positive t-lymphocytes/immunology	0.00014324390160591616	0.0003413680209308606	0.020833333333333336	0.8148056077504143	1	2
colitis/etiology	anti-bacterial agents/pharmacology	1.7873572066839927e-08	1.2662971396506933e-07	0.020833333333333336	0.8148056077504143	1	2
colitis/etiology	cytotoxicity immunologic	0.00014324390160591616	0.0003413680209308606	0.020833333333333336	0.8148056077504143	1	2
colitis/etiology	MTOR	0.00014324390160591616	0.0003413680209308606	0.020833333333333336	0.8148056077504143	1	2
glucocorticoids/pharmacology	melanoma/drug therapy	8.546906613060568e-05	0.00022842755525954715	0.05208333333333334	0.8148056077504143	1	2
glucocorticoids/pharmacology	immunosuppressive agents/pharmacology	2.338018667558117e-12	2.857578371459921e-11	0.010416666666666668	0.8148056077504143	1	2
glucocorticoids/pharmacology	mucositis/chemically induced	2.338018667558117e-12	2.857578371459921e-11	0.010416666666666668	0.8148056077504143	1	2
SNCA	tumor necrosis factor inhibitors	1.439032364380921e-07	9.08633728566805e-07	0.03125	0.8148056077504143	1	2
SNCA	TNF	0.0024133467566294087	0.004412856274151762	0.09178331466965287	0.8148056077504143	1	2
cd8-positive t-lymphocytes/immunology	drug synergism	0.0012390207660780694	0.002431505540941939	0.020833333333333336	0.8148056077504143	1	2
cd8-positive t-lymphocytes/immunology	cytotoxicity immunologic	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
cd8-positive t-lymphocytes/immunology	MTOR	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
prednisolone/therapeutic use	lung neoplasms/drug therapy	0.0	0.0	0.020833333333333332	0.8148056077504143	1	2
melanoma/drug therapy	vitamin d	3.2176306064002347e-10	2.6065302199133684e-09	0.05208333333333334	0.8148056077504143	1	2
melanoma/drug therapy	tumor necrosis factor inhibitors	1.0317260102477022e-05	3.9277001118719446e-05	0.05208333333333334	0.8148056077504143	1	2
melanoma/drug therapy	immunosuppressive agents/pharmacology	8.546906613060568e-05	0.00022842755525954715	0.05208333333333335	0.8148056077504143	1	2
melanoma/drug therapy	drug-related side effects and adverse reactions	0.0006172760765775775	0.0013724542553692947	0.10197368421052633	0.8148056077504143	1	2
melanoma/drug therapy	mucositis/chemically induced	8.546906613060568e-05	0.00022842755525954715	0.05208333333333335	0.8148056077504143	1	2
melanoma/drug therapy	TNF	4.6175276269266874e-07	2.7108518933361734e-06	0.0064389697648376265	0.5583234571556446	2	2
cytotoxicity immunologic	drug synergism	0.0012390207660780694	0.002431505540941939	0.020833333333333336	0.8148056077504143	1	2
cytotoxicity immunologic	MTOR	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
CD8A	colitis ulcerative/immunology	0.0007664463921124298	0.0016463236993987443	0.002192982456140351	0.5583234571556446	2	2
CD8A	colon/drug effects	0.005121409365443252	0.008846070722129253	0.006438969764837627	0.5583234571556446	2	2
CD8A	CD4	0.00010199086528106527	0.0002715425585190145	0.002192982456140351	0.5583234571556446	2	2
CD8A	cd8-positive t-lymphocytes/drug effects	0.0007664463921124298	0.0016463236993987443	0.002192982456140351	0.5583234571556446	2	2
CD8A	CD68	0.00010199086528106527	0.0002715425585190145	0.002192982456140351	0.5583234571556446	2	2
CD8A	phenotype	0.0007664463921124298	0.0016463236993987443	0.002192982456140351	0.5583234571556446	2	2
immunosuppressive agents/pharmacology	mucositis/chemically induced	2.338018667558117e-12	2.857578371459921e-11	0.010416666666666668	0.8148056077504143	1	2
MTOR	drug synergism	0.0012390207660780694	0.002431505540941939	0.020833333333333336	0.8148056077504143	1	2
psoriasis	dermatitis	2.338018667558117e-12	2.857578371459921e-11	0.010416666666666668	0.8148056077504143	1	2
psoriasis	rna	2.338018667558117e-12	2.857578371459921e-11	0.010416666666666668	0.8148056077504143	1	2
psoriasis	CXCL10	2.338018667558117e-12	2.857578371459921e-11	0.010416666666666668	0.8148056077504143	1	2
psoriasis	CXCL9	2.338018667558117e-12	2.857578371459921e-11	0.010416666666666668	0.8148056077504143	1	2
psoriasis	TCIM	2.338018667558117e-12	2.857578371459921e-11	0.010416666666666668	0.8148056077504143	1	2
psoriasis	TNF	4.535600525823469e-06	1.8159779883086303e-05	0.03125	0.8148056077504143	1	2
colitis ulcerative/immunology	pyrimidines/therapeutic use	0.0014117340488605246	0.0027446736391799967	0.041447368421052636	0.8148056077504143	1	2
colitis ulcerative/immunology	macrophages/drug effects	4.535600525823469e-06	1.8159779883086303e-05	0.020833333333333336	0.8148056077504143	1	2
colitis ulcerative/immunology	interferon-gamma/metabolism	6.252178968857436e-05	0.0001723885757903963	0.020833333333333336	0.8148056077504143	1	2
colitis ulcerative/immunology	immunologic memory/drug effects	6.252178968857436e-05	0.0001723885757903963	0.020833333333333336	0.8148056077504143	1	2
colitis ulcerative/immunology	colon/drug effects	4.6175276269266874e-07	2.7108518933361734e-06	0.0006578947368421054	0.5583234571556446	2	2
colitis ulcerative/immunology	crohn disease/immunology	4.535600525823469e-06	1.8159779883086303e-05	0.020833333333333336	0.8148056077504143	1	2
colitis ulcerative/immunology	piperidines/therapeutic use	0.0014117340488605246	0.0027446736391799967	0.041447368421052636	0.8148056077504143	1	2
colitis ulcerative/immunology	graft vs host disease/immunology	4.535600525823469e-06	1.8159779883086303e-05	0.020833333333333336	0.8148056077504143	1	2
colitis ulcerative/immunology	cd8-positive t-lymphocytes/drug effects	3.11462444724242e-09	2.375753684210459e-08	0.0002192982456140351	0.5583234571556446	2	2
colitis ulcerative/immunology	phenotype	3.11462444724242e-09	2.375753684210459e-08	0.0002192982456140351	0.5583234571556446	2	2
colitis ulcerative/immunology	CD4	0.0007366185030555084	0.0015904263134153022	0.041447368421052636	0.8148056077504143	1	2
colitis ulcerative/immunology	CD68	0.0007366185030555084	0.0015904263134153022	0.041447368421052636	0.8148056077504143	1	2
pyrimidines/therapeutic use	interferon-gamma/metabolism	1.6773537266145944e-05	5.6090708617992037e-05	0.020833333333333336	0.8148056077504143	1	2
pyrimidines/therapeutic use	immunologic memory/drug effects	1.6773537266145944e-05	5.6090708617992037e-05	0.020833333333333336	0.8148056077504143	1	2
pyrimidines/therapeutic use	protein kinase inhibitors/therapeutic use	3.387585545411298e-09	2.5559760974402934e-08	0.020833333333333336	0.8148056077504143	1	2
pyrimidines/therapeutic use	piperidines/therapeutic use	6.287970144569499e-12	7.383066068623738e-11	0.0002192982456140351	0.5583234571556446	2	2
pyrimidines/therapeutic use	cd8-positive t-lymphocytes/drug effects	0.0014117340488605246	0.0027446736391799967	0.041447368421052636	0.8148056077504143	1	2
pyrimidines/therapeutic use	phenotype	0.0014117340488605246	0.0027446736391799967	0.041447368421052636	0.8148056077504143	1	2
dermatitis	rna	2.338018667558117e-12	2.857578371459921e-11	0.010416666666666668	0.8148056077504143	1	2
dermatitis	CXCL10	2.338018667558117e-12	2.857578371459921e-11	0.010416666666666668	0.8148056077504143	1	2
dermatitis	CXCL9	2.338018667558117e-12	2.857578371459921e-11	0.010416666666666668	0.8148056077504143	1	2
dermatitis	TCIM	2.338018667558117e-12	2.857578371459921e-11	0.010416666666666668	0.8148056077504143	1	2
dermatitis	TNF	4.535600525823469e-06	1.8159779883086303e-05	0.03125	0.8148056077504143	1	2
macrophages/drug effects	colon/drug effects	8.546906613060568e-05	0.00022842755525954715	0.03125	0.8148056077504143	1	2
macrophages/drug effects	crohn disease/immunology	2.338018667558117e-12	2.857578371459921e-11	0.010416666666666668	0.8148056077504143	1	2
macrophages/drug effects	graft vs host disease/immunology	2.338018667558117e-12	2.857578371459921e-11	0.010416666666666668	0.8148056077504143	1	2
macrophages/drug effects	cd8-positive t-lymphocytes/drug effects	4.535600525823469e-06	1.8159779883086303e-05	0.020833333333333332	0.8148056077504143	1	2
macrophages/drug effects	phenotype	4.535600525823469e-06	1.8159779883086303e-05	0.020833333333333332	0.8148056077504143	1	2
macrophages/drug effects	CD4	1.9921871419192883e-07	1.2033731579801481e-06	0.020833333333333332	0.8148056077504143	1	2
macrophages/drug effects	CD68	1.9921871419192883e-07	1.2033731579801481e-06	0.020833333333333332	0.8148056077504143	1	2
interferon-gamma/metabolism	immunologic memory/drug effects	7.853117489631245e-08	5.14514594148254e-07	0.010416666666666668	0.8148056077504143	1	2
interferon-gamma/metabolism	colon/drug effects	0.0006172760765775775	0.0013724542553692947	0.03125	0.8148056077504143	1	2
interferon-gamma/metabolism	piperidines/therapeutic use	1.6773537266145944e-05	5.6090708617992037e-05	0.020833333333333332	0.8148056077504143	1	2
interferon-gamma/metabolism	ctla-4 antigen/antagonists & inhibitors	0.0007599376534438429	0.001637391438863538	0.03125	0.8148056077504143	1	2
interferon-gamma/metabolism	cd8-positive t-lymphocytes/drug effects	6.252178968857436e-05	0.0001723885757903963	0.020833333333333332	0.8148056077504143	1	2
interferon-gamma/metabolism	phenotype	6.252178968857436e-05	0.0001723885757903963	0.020833333333333332	0.8148056077504143	1	2
immunologic memory/drug effects	colon/drug effects	0.0006172760765775775	0.0013724542553692947	0.03125	0.8148056077504143	1	2
immunologic memory/drug effects	piperidines/therapeutic use	1.6773537266145944e-05	5.6090708617992037e-05	0.020833333333333332	0.8148056077504143	1	2
immunologic memory/drug effects	ctla-4 antigen/antagonists & inhibitors	0.0007599376534438429	0.001637391438863538	0.03125	0.8148056077504143	1	2
immunologic memory/drug effects	cd8-positive t-lymphocytes/drug effects	6.252178968857436e-05	0.0001723885757903963	0.020833333333333332	0.8148056077504143	1	2
immunologic memory/drug effects	phenotype	6.252178968857436e-05	0.0001723885757903963	0.020833333333333332	0.8148056077504143	1	2
colon/drug effects	protective agents/pharmacology	1.0317260102477022e-05	3.9277001118719446e-05	0.03125	0.8148056077504143	1	2
colon/drug effects	mesalamine/pharmacology	1.0317260102477022e-05	3.9277001118719446e-05	0.03125	0.8148056077504143	1	2
colon/drug effects	trinitrobenzenesulfonic acid/adverse effects	1.0317260102477022e-05	3.9277001118719446e-05	0.03125	0.8148056077504143	1	2
colon/drug effects	graft vs host disease/immunology	8.546906613060568e-05	0.00022842755525954715	0.03125	0.8148056077504143	1	2
colon/drug effects	cd8-positive t-lymphocytes/drug effects	4.6175276269266874e-07	2.7108518933361734e-06	0.0006578947368421052	0.5583234571556446	2	2
colon/drug effects	phenotype	4.6175276269266874e-07	2.7108518933361734e-06	0.0006578947368421052	0.5583234571556446	2	2
colon/drug effects	ACAD8	0.0021653636426707257	0.004033520510857234	0.06184210526315789	0.8148056077504143	1	2
colon/drug effects	CD4	0.00399310851743373	0.0070546042277569694	0.06184210526315789	0.8148056077504143	1	2
colon/drug effects	CD68	0.00399310851743373	0.0070546042277569694	0.06184210526315789	0.8148056077504143	1	2
colon/drug effects	crohn disease/immunology	8.546906613060568e-05	0.00022842755525954715	0.03125	0.8148056077504143	1	2
melanoma/genetics	receptors cxcr6/genetics	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
melanoma/genetics	receptors cxcr3/genetics	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
receptors cxcr6/genetics	receptors cxcr3/genetics	3.528349898473948e-06	1.463145096787808e-05	0.010416666666666668	0.8148056077504143	1	2
rna	CXCL10	2.338018667558117e-12	2.857578371459921e-11	0.010416666666666668	0.8148056077504143	1	2
rna	CXCL9	2.338018667558117e-12	2.857578371459921e-11	0.010416666666666668	0.8148056077504143	1	2
rna	TCIM	2.338018667558117e-12	2.857578371459921e-11	0.010416666666666668	0.8148056077504143	1	2
rna	TNF	4.535600525823469e-06	1.8159779883086303e-05	0.03125	0.8148056077504143	1	2
CXCL10	CXCL9	2.338018667558117e-12	2.857578371459921e-11	0.010416666666666668	0.8148056077504143	1	2
CXCL10	TCIM	2.338018667558117e-12	2.857578371459921e-11	0.010416666666666668	0.8148056077504143	1	2
CXCL10	TNF	4.535600525823469e-06	1.8159779883086303e-05	0.03125	0.8148056077504143	1	2
CXCL9	TCIM	2.338018667558117e-12	2.857578371459921e-11	0.010416666666666668	0.8148056077504143	1	2
CXCL9	TNF	4.535600525823469e-06	1.8159779883086303e-05	0.03125	0.8148056077504143	1	2
crohn disease/immunology	graft vs host disease/immunology	2.338018667558117e-12	2.857578371459921e-11	0.010416666666666668	0.8148056077504143	1	2
crohn disease/immunology	cd8-positive t-lymphocytes/drug effects	4.535600525823469e-06	1.8159779883086303e-05	0.020833333333333332	0.8148056077504143	1	2
crohn disease/immunology	phenotype	4.535600525823469e-06	1.8159779883086303e-05	0.020833333333333332	0.8148056077504143	1	2
crohn disease/immunology	CD4	1.9921871419192883e-07	1.2033731579801481e-06	0.020833333333333332	0.8148056077504143	1	2
crohn disease/immunology	CD68	1.9921871419192883e-07	1.2033731579801481e-06	0.020833333333333332	0.8148056077504143	1	2
TCIM	TNF	4.535600525823469e-06	1.8159779883086303e-05	0.03125	0.8148056077504143	1	2
TNF	tumor necrosis factor inhibitors	2.71985991617818e-07	1.6195177278667796e-06	0.03125	0.8148056077504143	1	2
TNF	drug-related side effects and adverse reactions	6.252178968857436e-05	0.0001723885757903963	0.0618421052631579	0.8148056077504143	1	2
carcinoma non-small-cell lung	cd8-positive t-lymphocytes	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
piperidines/therapeutic use	protein kinase inhibitors/therapeutic use	3.387585545411298e-09	2.5559760974402934e-08	0.020833333333333332	0.8148056077504143	1	2
piperidines/therapeutic use	cd8-positive t-lymphocytes/drug effects	0.0014117340488605246	0.0027446736391799967	0.041447368421052636	0.8148056077504143	1	2
piperidines/therapeutic use	phenotype	0.0014117340488605246	0.0027446736391799967	0.041447368421052636	0.8148056077504143	1	2
ctla-4 antigen/antagonists & inhibitors	lymphocytes/drug effects	0.00023665255967086907	0.0005538676928467149	0.03125	0.8148056077504143	1	2
ctla-4 antigen/antagonists & inhibitors	vitamin d/administration & dosage	0.00023665255967086907	0.0005538676928467149	0.03125	0.8148056077504143	1	2
ctla-4 antigen/antagonists & inhibitors	neutrophils/drug effects	0.00023665255967086907	0.0005538676928467149	0.03125	0.8148056077504143	1	2
ctla-4 antigen/antagonists & inhibitors	antibodies monoclonal/adverse effects	0.00023665255967086907	0.0005538676928467149	0.03125	0.8148056077504143	1	2
graft vs host disease/immunology	cd8-positive t-lymphocytes/drug effects	4.535600525823469e-06	1.8159779883086303e-05	0.020833333333333332	0.8148056077504143	1	2
graft vs host disease/immunology	phenotype	4.535600525823469e-06	1.8159779883086303e-05	0.020833333333333332	0.8148056077504143	1	2
graft vs host disease/immunology	CD4	1.9921871419192883e-07	1.2033731579801481e-06	0.020833333333333332	0.8148056077504143	1	2
graft vs host disease/immunology	CD68	1.9921871419192883e-07	1.2033731579801481e-06	0.020833333333333332	0.8148056077504143	1	2
cd8-positive t-lymphocytes/drug effects	phenotype	3.11462444724242e-09	2.375753684210459e-08	0.0002192982456140351	0.5583234571556446	2	2
cd8-positive t-lymphocytes/drug effects	CD4	0.0007366185030555084	0.0015904263134153022	0.041447368421052636	0.8148056077504143	1	2
cd8-positive t-lymphocytes/drug effects	CD68	0.0007366185030555084	0.0015904263134153022	0.041447368421052636	0.8148056077504143	1	2
phenotype	CD4	0.0007366185030555084	0.0015904263134153022	0.041447368421052636	0.8148056077504143	1	2
phenotype	CD68	0.0007366185030555084	0.0015904263134153022	0.041447368421052636	0.8148056077504143	1	2
urothelium/drug effects	carcinoma non-small-cell lung/complications	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
urothelium/drug effects	drug-related side effects and adverse reactions	6.210254532845738e-12	7.383066068623738e-11	0.020833333333333332	0.8148056077504143	1	2
urothelium/drug effects	melanoma/complications	2.71985991617818e-07	1.6195177278667796e-06	0.03125	0.8148056077504143	1	2
urothelium/drug effects	infliximab/administration & dosage	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
urothelium/drug effects	ACAD8	6.120524087549484e-10	4.827130318105065e-09	0.020833333333333332	0.8148056077504143	1	2
urothelium/drug effects	CRP	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
CD4	CD68	1.6542323066914832e-14	2.76587641678816e-13	0.0002192982456140351	0.5583234571556446	2	2
carcinoma non-small-cell lung/complications	drug-related side effects and adverse reactions	6.210254532845738e-12	7.383066068623738e-11	0.020833333333333332	0.8148056077504143	1	2
carcinoma non-small-cell lung/complications	melanoma/complications	2.71985991617818e-07	1.6195177278667796e-06	0.03125	0.8148056077504143	1	2
carcinoma non-small-cell lung/complications	infliximab/administration & dosage	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
carcinoma non-small-cell lung/complications	ACAD8	6.120524087549484e-10	4.827130318105065e-09	0.020833333333333332	0.8148056077504143	1	2
carcinoma non-small-cell lung/complications	CRP	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
drug-related side effects and adverse reactions	melanoma/complications	6.252178968857436e-05	0.0001723885757903963	0.0618421052631579	0.8148056077504143	1	2
drug-related side effects and adverse reactions	infliximab/administration & dosage	6.210254532845738e-12	7.383066068623738e-11	0.020833333333333336	0.8148056077504143	1	2
drug-related side effects and adverse reactions	ACAD8	1.3751695258079621e-06	7.767849483617948e-06	0.041447368421052636	0.8148056077504143	1	2
drug-related side effects and adverse reactions	CRP	6.210254532845738e-12	7.383066068623738e-11	0.020833333333333336	0.8148056077504143	1	2
melanoma/complications	colitis collagenous/drug therapy	2.574607194105738e-13	4.0764613906674185e-12	0.03125	0.8148056077504143	1	2
melanoma/complications	skin neoplasms/complications	2.574607194105738e-13	4.0764613906674185e-12	0.03125	0.8148056077504143	1	2
melanoma/complications	lymphocytes/drug effects	1.2702374157291807e-05	4.792050900494562e-05	0.03125	0.8148056077504143	1	2
melanoma/complications	vitamin d/administration & dosage	1.2702374157291807e-05	4.792050900494562e-05	0.03125	0.8148056077504143	1	2
melanoma/complications	immune checkpoint inhibitors/pharmacology	0.003785246270538556	0.006698700004594057	0.12108062709966406	0.8148056077504143	1	2
melanoma/complications	infliximab/administration & dosage	2.71985991617818e-07	1.6195177278667796e-06	0.03125	0.8148056077504143	1	2
melanoma/complications	ACAD8	0.000328675335596218	0.0007582024849846529	0.06184210526315789	0.8148056077504143	1	2
melanoma/complications	CRP	2.71985991617818e-07	1.6195177278667796e-06	0.03125	0.8148056077504143	1	2
melanoma/complications	neutrophils/drug effects	1.2702374157291807e-05	4.792050900494562e-05	0.03125	0.8148056077504143	1	2
melanoma/complications	antibodies monoclonal/adverse effects	1.2702374157291807e-05	4.792050900494562e-05	0.03125	0.8148056077504143	1	2
infliximab/administration & dosage	ACAD8	6.120524087549484e-10	4.827130318105065e-09	0.020833333333333332	0.8148056077504143	1	2
infliximab/administration & dosage	CRP	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
thyroiditis/diagnostic imaging	myocarditis/diagnostic imaging	1.932526361159148e-10	1.5777265995400858e-09	0.010416666666666668	0.8148056077504143	1	2
thyroiditis/diagnostic imaging	pancreatitis/diagnostic imaging	1.932526361159148e-10	1.5777265995400858e-09	0.010416666666666668	0.8148056077504143	1	2
thyroiditis/diagnostic imaging	neoplasms/diagnostic imaging	4.970686195981955e-09	3.619767996377103e-08	0.020833333333333332	0.8148056077504143	1	2
thyroiditis/diagnostic imaging	sarcoidosis/diagnostic imaging	1.932526361159148e-10	1.5777265995400858e-09	0.010416666666666668	0.8148056077504143	1	2
thyroiditis/diagnostic imaging	hepatitis/diagnostic imaging	1.932526361159148e-10	1.5777265995400858e-09	0.010416666666666668	0.8148056077504143	1	2
thyroiditis/diagnostic imaging	pericarditis/diagnostic imaging	1.932526361159148e-10	1.5777265995400858e-09	0.010416666666666668	0.8148056077504143	1	2
thyroiditis/diagnostic imaging	encephalitis/diagnostic imaging	1.932526361159148e-10	1.5777265995400858e-09	0.010416666666666668	0.8148056077504143	1	2
thyroiditis/diagnostic imaging	colitis/diagnostic imaging	1.932526361159148e-10	1.5777265995400858e-09	0.010416666666666668	0.8148056077504143	1	2
myocarditis/diagnostic imaging	pancreatitis/diagnostic imaging	1.932526361159148e-10	1.5777265995400858e-09	0.010416666666666668	0.8148056077504143	1	2
myocarditis/diagnostic imaging	neoplasms/diagnostic imaging	4.970686195981955e-09	3.619767996377103e-08	0.020833333333333332	0.8148056077504143	1	2
myocarditis/diagnostic imaging	sarcoidosis/diagnostic imaging	1.932526361159148e-10	1.5777265995400858e-09	0.010416666666666668	0.8148056077504143	1	2
myocarditis/diagnostic imaging	hepatitis/diagnostic imaging	1.932526361159148e-10	1.5777265995400858e-09	0.010416666666666668	0.8148056077504143	1	2
myocarditis/diagnostic imaging	pericarditis/diagnostic imaging	1.932526361159148e-10	1.5777265995400858e-09	0.010416666666666668	0.8148056077504143	1	2
myocarditis/diagnostic imaging	encephalitis/diagnostic imaging	1.932526361159148e-10	1.5777265995400858e-09	0.010416666666666668	0.8148056077504143	1	2
myocarditis/diagnostic imaging	colitis/diagnostic imaging	1.932526361159148e-10	1.5777265995400858e-09	0.010416666666666668	0.8148056077504143	1	2
ACAD8	protective agents/pharmacology	6.120524087549484e-10	4.827130318105065e-09	0.020833333333333332	0.8148056077504143	1	2
ACAD8	mesalamine/pharmacology	6.120524087549484e-10	4.827130318105065e-09	0.020833333333333332	0.8148056077504143	1	2
ACAD8	CRP	6.120524087549484e-10	4.827130318105065e-09	0.020833333333333336	0.8148056077504143	1	2
ACAD8	immune checkpoint inhibitors/pharmacology	0.0004445142708253691	0.0010054489459145255	0.08201754385964913	0.8148056077504143	1	2
ACAD8	trinitrobenzenesulfonic acid/adverse effects	6.120524087549484e-10	4.827130318105065e-09	0.020833333333333332	0.8148056077504143	1	2
pancreatitis/diagnostic imaging	neoplasms/diagnostic imaging	4.970686195981955e-09	3.619767996377103e-08	0.020833333333333332	0.8148056077504143	1	2
pancreatitis/diagnostic imaging	sarcoidosis/diagnostic imaging	1.932526361159148e-10	1.5777265995400858e-09	0.010416666666666668	0.8148056077504143	1	2
pancreatitis/diagnostic imaging	hepatitis/diagnostic imaging	1.932526361159148e-10	1.5777265995400858e-09	0.010416666666666668	0.8148056077504143	1	2
pancreatitis/diagnostic imaging	pericarditis/diagnostic imaging	1.932526361159148e-10	1.5777265995400858e-09	0.010416666666666668	0.8148056077504143	1	2
pancreatitis/diagnostic imaging	encephalitis/diagnostic imaging	1.932526361159148e-10	1.5777265995400858e-09	0.010416666666666668	0.8148056077504143	1	2
pancreatitis/diagnostic imaging	colitis/diagnostic imaging	1.932526361159148e-10	1.5777265995400858e-09	0.010416666666666668	0.8148056077504143	1	2
neoplasms/diagnostic imaging	sarcoidosis/diagnostic imaging	4.970686195981955e-09	3.619767996377103e-08	0.020833333333333336	0.8148056077504143	1	2
neoplasms/diagnostic imaging	hepatitis/diagnostic imaging	4.970686195981955e-09	3.619767996377103e-08	0.020833333333333336	0.8148056077504143	1	2
neoplasms/diagnostic imaging	pericarditis/diagnostic imaging	4.970686195981955e-09	3.619767996377103e-08	0.020833333333333336	0.8148056077504143	1	2
neoplasms/diagnostic imaging	encephalitis/diagnostic imaging	4.970686195981955e-09	3.619767996377103e-08	0.020833333333333336	0.8148056077504143	1	2
neoplasms/diagnostic imaging	colitis/diagnostic imaging	4.970686195981955e-09	3.619767996377103e-08	0.020833333333333336	0.8148056077504143	1	2
sarcoidosis/diagnostic imaging	hepatitis/diagnostic imaging	1.932526361159148e-10	1.5777265995400858e-09	0.010416666666666668	0.8148056077504143	1	2
sarcoidosis/diagnostic imaging	pericarditis/diagnostic imaging	1.932526361159148e-10	1.5777265995400858e-09	0.010416666666666668	0.8148056077504143	1	2
sarcoidosis/diagnostic imaging	encephalitis/diagnostic imaging	1.932526361159148e-10	1.5777265995400858e-09	0.010416666666666668	0.8148056077504143	1	2
sarcoidosis/diagnostic imaging	colitis/diagnostic imaging	1.932526361159148e-10	1.5777265995400858e-09	0.010416666666666668	0.8148056077504143	1	2
hepatitis/diagnostic imaging	pericarditis/diagnostic imaging	1.932526361159148e-10	1.5777265995400858e-09	0.010416666666666668	0.8148056077504143	1	2
hepatitis/diagnostic imaging	encephalitis/diagnostic imaging	1.932526361159148e-10	1.5777265995400858e-09	0.010416666666666668	0.8148056077504143	1	2
hepatitis/diagnostic imaging	colitis/diagnostic imaging	1.932526361159148e-10	1.5777265995400858e-09	0.010416666666666668	0.8148056077504143	1	2
pericarditis/diagnostic imaging	encephalitis/diagnostic imaging	1.932526361159148e-10	1.5777265995400858e-09	0.010416666666666668	0.8148056077504143	1	2
pericarditis/diagnostic imaging	colitis/diagnostic imaging	1.932526361159148e-10	1.5777265995400858e-09	0.010416666666666668	0.8148056077504143	1	2
encephalitis/diagnostic imaging	colitis/diagnostic imaging	1.932526361159148e-10	1.5777265995400858e-09	0.010416666666666668	0.8148056077504143	1	2
host microbial interactions/drug effects	metabolome/drug effects	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
host microbial interactions/drug effects	dysbiosis/etiology	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
host microbial interactions/drug effects	neoplasms/complications	1.2957063200147445e-09	9.99271663775209e-09	0.03125	0.8148056077504143	1	2
host microbial interactions/drug effects	anti-bacterial agents/pharmacology	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
metabolome/drug effects	dysbiosis/etiology	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
metabolome/drug effects	neoplasms/complications	1.2957063200147445e-09	9.99271663775209e-09	0.03125	0.8148056077504143	1	2
metabolome/drug effects	anti-bacterial agents/pharmacology	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
immune system diseases/drug therapy	gastrointestinal neoplasms/drug therapy	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
immune system diseases/drug therapy	BTLA	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
immune system diseases/drug therapy	CD28	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
immune system diseases/drug therapy	CSF2	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
immune system diseases/drug therapy	HAVCR2	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
immune system diseases/drug therapy	IL15	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
immune system diseases/drug therapy	IL17C	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
immune system diseases/drug therapy	IL21	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
immune system diseases/drug therapy	IL22	0.0003691560576504216	0.0008377157008570913	0.020833333333333332	0.8148056077504143	1	2
immune system diseases/drug therapy	IL4	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
immune system diseases/drug therapy	LIF	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
protective agents/pharmacology	mesalamine/pharmacology	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
protective agents/pharmacology	immune checkpoint inhibitors/pharmacology	4.879238649779793e-07	2.840559548200493e-06	0.041666666666666664	0.8148056077504143	1	2
protective agents/pharmacology	trinitrobenzenesulfonic acid/adverse effects	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
mesalamine/pharmacology	immune checkpoint inhibitors/pharmacology	4.879238649779793e-07	2.840559548200493e-06	0.041666666666666664	0.8148056077504143	1	2
mesalamine/pharmacology	trinitrobenzenesulfonic acid/adverse effects	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
dysbiosis/etiology	neoplasms/complications	1.2957063200147445e-09	9.99271663775209e-09	0.03125	0.8148056077504143	1	2
dysbiosis/etiology	anti-bacterial agents/pharmacology	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
neoplasms/complications	colitis/epidemiology	5.3053783588552506e-11	5.866794058205013e-10	0.03125	0.8148056077504143	1	2
neoplasms/complications	b7-h1 antigen/antagonists & inhibitors	0.0004131510806429928	0.0009355208651612729	0.09178331466965287	0.8148056077504143	1	2
neoplasms/complications	inflammatory bowel diseases/complications	9.383302490562073e-08	6.090404411576004e-07	0.06184210526315789	0.8148056077504143	1	2
neoplasms/complications	anti-bacterial agents/pharmacology	1.2957063200147445e-09	9.99271663775209e-09	0.03125	0.8148056077504143	1	2
immune checkpoint inhibitors/pharmacology	tryptophan/pharmacology	1.621400791407268e-10	1.5777265995400858e-09	0.041666666666666664	0.8148056077504143	1	2
immune checkpoint inhibitors/pharmacology	colitis collagenous/drug therapy	8.120171202108395e-13	1.247879250912246e-11	0.041666666666666664	0.8148056077504143	1	2
immune checkpoint inhibitors/pharmacology	programmed cell death 1 receptor/metabolism	7.173081661981939e-08	4.714383859604482e-07	0.041666666666666664	0.8148056077504143	1	2
immune checkpoint inhibitors/pharmacology	skin neoplasms/complications	8.120171202108395e-13	1.247879250912246e-11	0.041666666666666664	0.8148056077504143	1	2
immune checkpoint inhibitors/pharmacology	colitis/diagnosis	1.9534764438389196e-05	6.521990044126745e-05	0.08201754385964914	0.8148056077504143	1	2
immune checkpoint inhibitors/pharmacology	trinitrobenzenesulfonic acid/adverse effects	4.879238649779793e-07	2.840559548200493e-06	0.041666666666666664	0.8148056077504143	1	2
immune checkpoint inhibitors/pharmacology	gastrointestinal tract/metabolism	7.173081661981939e-08	4.714383859604482e-07	0.041666666666666664	0.8148056077504143	1	2
immune checkpoint inhibitors/pharmacology	b7-h1 antigen/metabolism	7.173081661981939e-08	4.714383859604482e-07	0.041666666666666664	0.8148056077504143	1	2
immune checkpoint inhibitors/pharmacology	AHR	1.621400791407268e-10	1.5777265995400858e-09	0.041666666666666664	0.8148056077504143	1	2
immune checkpoint inhibitors/pharmacology	IL22	0.0030212104973605935	0.005495500382492289	0.08201754385964913	0.8148056077504143	1	2
pneumonia	ligands	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
gastrointestinal neoplasms/drug therapy	BTLA	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
gastrointestinal neoplasms/drug therapy	CD28	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
gastrointestinal neoplasms/drug therapy	CSF2	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
gastrointestinal neoplasms/drug therapy	HAVCR2	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
gastrointestinal neoplasms/drug therapy	IL15	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
gastrointestinal neoplasms/drug therapy	IL17C	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
gastrointestinal neoplasms/drug therapy	IL21	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
gastrointestinal neoplasms/drug therapy	IL22	0.0003691560576504216	0.0008377157008570913	0.020833333333333332	0.8148056077504143	1	2
gastrointestinal neoplasms/drug therapy	IL4	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
gastrointestinal neoplasms/drug therapy	LIF	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
adrenal cortex hormones/therapeutic use	tumor necrosis factor inhibitors	2.6149767126781853e-05	8.688873337833716e-05	0.041666666666666664	0.8148056077504143	1	2
adrenal cortex hormones/therapeutic use	biological products/therapeutic use	8.588607558479566e-08	5.591959438387007e-07	0.041666666666666664	0.8148056077504143	1	2
adrenal cortex hormones/therapeutic use	beclomethasone/adverse effects	8.588607558479566e-08	5.591959438387007e-07	0.041666666666666664	0.8148056077504143	1	2
adrenal cortex hormones/therapeutic use	antineoplastic agents/adverse effects	0.003518649881307012	0.006237470951595977	0.041666666666666664	0.8148056077504143	1	2
adrenal cortex hormones/therapeutic use	intestinal mucosa/chemistry	0.003518649881307012	0.006237470951595977	0.041666666666666664	0.8148056077504143	1	2
adrenal cortex hormones/therapeutic use	leukemia lymphocytic chronic b-cell/drug therapy	0.003518649881307012	0.006237470951595977	0.041666666666666664	0.8148056077504143	1	2
adrenal cortex hormones/therapeutic use	class i phosphatidylinositol 3-kinases/antagonists & inhibitors	0.003518649881307012	0.006237470951595977	0.041666666666666664	0.8148056077504143	1	2
adrenal cortex hormones/therapeutic use	purines/adverse effects	0.003518649881307012	0.006237470951595977	0.041666666666666664	0.8148056077504143	1	2
adrenal cortex hormones/therapeutic use	colon/chemistry	0.003518649881307012	0.006237470951595977	0.041666666666666664	0.8148056077504143	1	2
adrenal cortex hormones/therapeutic use	lymphocytosis/chemically induced	0.003518649881307012	0.006237470951595977	0.041666666666666664	0.8148056077504143	1	2
adrenal cortex hormones/therapeutic use	protein kinase inhibitors/adverse effects	0.003518649881307012	0.006237470951595977	0.041666666666666664	0.8148056077504143	1	2
adrenal cortex hormones/therapeutic use	apoptosis/drug effects	0.003518649881307012	0.006237470951595977	0.041666666666666664	0.8148056077504143	1	2
adrenal cortex hormones/therapeutic use	quinazolinones/adverse effects	0.003518649881307012	0.006237470951595977	0.041666666666666664	0.8148056077504143	1	2
adrenal cortex hormones/therapeutic use	lymphoma non-hodgkin/drug therapy	0.003518649881307012	0.006237470951595977	0.041666666666666664	0.8148056077504143	1	2
adrenal cortex hormones/therapeutic use	PIK3CD	0.003518649881307012	0.006237470951595977	0.041666666666666664	0.8148056077504143	1	2
BTLA	CD28	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
BTLA	CSF2	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
BTLA	HAVCR2	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
BTLA	IL15	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
BTLA	IL17C	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
BTLA	IL21	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
BTLA	IL22	0.0003691560576504216	0.0008377157008570913	0.020833333333333332	0.8148056077504143	1	2
BTLA	IL4	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
BTLA	LIF	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
CD274	b7-h1 antigen/antagonists & inhibitors	0.00010242254680248308	0.0002723449399709792	0.0031844904815229564	0.32151609391373515	3	2
CD28	CSF2	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
CD28	HAVCR2	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
CD28	IL15	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
CD28	IL17C	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
CD28	IL21	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
CD28	IL22	0.0003691560576504216	0.0008377157008570913	0.020833333333333332	0.8148056077504143	1	2
CD28	IL4	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
CD28	LIF	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
CSF2	HAVCR2	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
CSF2	IL15	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
CSF2	IL17C	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
CSF2	IL21	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
CSF2	IL22	0.0003691560576504216	0.0008377157008570913	0.020833333333333332	0.8148056077504143	1	2
CSF2	IL4	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
CSF2	LIF	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
HAVCR2	IL15	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
HAVCR2	IL17C	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
HAVCR2	IL21	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
HAVCR2	IL22	0.0003691560576504216	0.0008377157008570913	0.020833333333333332	0.8148056077504143	1	2
HAVCR2	IL4	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
HAVCR2	LIF	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
IL15	IL17C	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
IL15	IL21	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
IL15	IL22	0.0003691560576504216	0.0008377157008570913	0.020833333333333332	0.8148056077504143	1	2
IL15	IL4	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
IL15	LIF	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
IL17C	IL21	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
IL17C	IL22	0.0003691560576504216	0.0008377157008570913	0.020833333333333332	0.8148056077504143	1	2
IL17C	IL4	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
IL17C	LIF	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
IL21	IL22	0.0003691560576504216	0.0008377157008570913	0.020833333333333332	0.8148056077504143	1	2
IL21	IL4	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
IL21	LIF	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
IL22	tryptophan/pharmacology	2.3560930983990147e-11	2.633280521740075e-10	0.020833333333333332	0.8148056077504143	1	2
IL22	AHR	2.3560930983990147e-11	2.633280521740075e-10	0.020833333333333332	0.8148056077504143	1	2
IL22	IL4	0.0003691560576504216	0.0008377157008570913	0.020833333333333336	0.8148056077504143	1	2
IL22	LIF	0.0003691560576504216	0.0008377157008570913	0.020833333333333336	0.8148056077504143	1	2
interleukin-17/genetics	micrornas/genetics	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
interleukin-17/genetics	gene expression regulation neoplastic	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
interleukin-17/genetics	lymphocytes tumor-infiltrating/metabolism	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
interleukin-17/genetics	t-lymphocytes cytotoxic/immunology	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
interleukin-17/genetics	tumor microenvironment/drug effects	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
interleukin-17/genetics	ht29 cells	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
interleukin-17/genetics	colorectal neoplasms/drug therapy	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
interleukin-17/genetics	b7-h1 antigen/genetics	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
interleukin-17/genetics	MIR15B	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
interleukin-17/genetics	NRF1	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
micrornas/genetics	gene expression regulation neoplastic	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
micrornas/genetics	lymphocytes tumor-infiltrating/metabolism	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
micrornas/genetics	t-lymphocytes cytotoxic/immunology	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
micrornas/genetics	tumor microenvironment/drug effects	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
micrornas/genetics	ht29 cells	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
micrornas/genetics	colorectal neoplasms/drug therapy	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
micrornas/genetics	b7-h1 antigen/genetics	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
micrornas/genetics	MIR15B	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
micrornas/genetics	NRF1	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
IL4	LIF	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
gene expression regulation neoplastic	lymphocytes tumor-infiltrating/metabolism	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
gene expression regulation neoplastic	t-lymphocytes cytotoxic/immunology	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
gene expression regulation neoplastic	tumor microenvironment/drug effects	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
gene expression regulation neoplastic	ht29 cells	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
gene expression regulation neoplastic	colorectal neoplasms/drug therapy	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
gene expression regulation neoplastic	b7-h1 antigen/genetics	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
gene expression regulation neoplastic	MIR15B	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
gene expression regulation neoplastic	NRF1	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
lymphocytes tumor-infiltrating/metabolism	colorectal neoplasms/drug therapy	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
lymphocytes tumor-infiltrating/metabolism	b7-h1 antigen/genetics	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
lymphocytes tumor-infiltrating/metabolism	MIR15B	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
lymphocytes tumor-infiltrating/metabolism	NRF1	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
lymphocytes tumor-infiltrating/metabolism	t-lymphocytes cytotoxic/immunology	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
lymphocytes tumor-infiltrating/metabolism	tumor microenvironment/drug effects	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
lymphocytes tumor-infiltrating/metabolism	ht29 cells	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
neoplasms/drug therapy	glucocorticoids/therapeutic use	0.003110882856322661	0.0056389810665345725	0.125	0.8148056077504143	1	2
neoplasms/drug therapy	escherichia coli infections/drug therapy	0.0007251493636150075	0.0015904263134153022	0.125	0.8148056077504143	1	2
neoplasms/drug therapy	tryptophan/pharmacology	5.548986913805898e-05	0.00015463176866472436	0.125	0.8148056077504143	1	2
neoplasms/drug therapy	virus diseases/etiology	0.0007251493636150075	0.0015904263134153022	0.125	0.8148056077504143	1	2
neoplasms/drug therapy	chemical and drug induced liver injury/diagnosis	1.563055052056228e-07	9.78079358921412e-07	0.125	0.8148056077504143	1	2
neoplasms/drug therapy	disease progression	0.003110882856322661	0.0056389810665345725	0.125	0.8148056077504143	1	2
neoplasms/drug therapy	clostridium infections/chemically induced	0.0007251493636150075	0.0015904263134153022	0.12500000000000003	0.8148056077504143	1	2
neoplasms/drug therapy	abdominal pain/chemically induced	0.003110882856322661	0.0056389810665345725	0.12500000000000003	0.8148056077504143	1	2
neoplasms/drug therapy	anti-bacterial agents/adverse effects	0.0007251493636150075	0.0015904263134153022	0.12500000000000003	0.8148056077504143	1	2
neoplasms/drug therapy	intestinal mucosa/immunology	6.046895137057362e-06	2.3755659467011068e-05	0.12500000000000003	0.8148056077504143	1	2
neoplasms/drug therapy	colon/immunology	3.0369473602576136e-10	2.4697354019215612e-09	0.014473684210526316	0.5583234571556446	2	2
neoplasms/drug therapy	t-lymphocyte subsets/immunology	6.046895137057362e-06	2.3755659467011068e-05	0.12500000000000003	0.8148056077504143	1	2
neoplasms/drug therapy	gastritis/complications	0.003110882856322661	0.0056389810665345725	0.12500000000000003	0.8148056077504143	1	2
neoplasms/drug therapy	biological products/therapeutic use	5.548986913805898e-05	0.00015463176866472436	0.12500000000000003	0.8148056077504143	1	2
neoplasms/drug therapy	hepatitis/diagnosis	1.563055052056228e-07	9.78079358921412e-07	0.12500000000000003	0.8148056077504143	1	2
neoplasms/drug therapy	butyrates/metabolism	1.563055052056228e-07	9.78079358921412e-07	0.12500000000000003	0.8148056077504143	1	2
neoplasms/drug therapy	AHR	5.548986913805898e-05	0.00015463176866472436	0.12500000000000003	0.8148056077504143	1	2
neoplasms/drug therapy	protein kinase inhibitors/therapeutic use	0.0007251493636150075	0.0015904263134153022	0.125	0.8148056077504143	1	2
t-lymphocytes cytotoxic/immunology	MIR15B	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
t-lymphocytes cytotoxic/immunology	NRF1	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
t-lymphocytes cytotoxic/immunology	tumor microenvironment/drug effects	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
t-lymphocytes cytotoxic/immunology	ht29 cells	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
t-lymphocytes cytotoxic/immunology	colorectal neoplasms/drug therapy	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
t-lymphocytes cytotoxic/immunology	b7-h1 antigen/genetics	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
tumor microenvironment/drug effects	ht29 cells	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
tumor microenvironment/drug effects	colorectal neoplasms/drug therapy	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
tumor microenvironment/drug effects	b7-h1 antigen/genetics	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
tumor microenvironment/drug effects	MIR15B	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
tumor microenvironment/drug effects	NRF1	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
glucocorticoids/therapeutic use	disease progression	6.106226635438361e-15	1.0291946506504979e-13	0.010416666666666668	0.8148056077504143	1	2
glucocorticoids/therapeutic use	abdominal pain/chemically induced	6.106226635438361e-15	1.0291946506504979e-13	0.010416666666666668	0.8148056077504143	1	2
glucocorticoids/therapeutic use	gastritis/complications	6.106226635438361e-15	1.0291946506504979e-13	0.010416666666666668	0.8148056077504143	1	2
glucocorticoids/therapeutic use	enterocolitis/chemically induced	1.5354717497473303e-11	1.744095628789087e-10	0.020833333333333332	0.8148056077504143	1	2
ht29 cells	colorectal neoplasms/drug therapy	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
ht29 cells	b7-h1 antigen/genetics	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
ht29 cells	MIR15B	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
ht29 cells	NRF1	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
colorectal neoplasms/drug therapy	b7-h1 antigen/genetics	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
colorectal neoplasms/drug therapy	MIR15B	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
colorectal neoplasms/drug therapy	NRF1	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
b7-h1 antigen/genetics	MIR15B	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
b7-h1 antigen/genetics	NRF1	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
disease progression	abdominal pain/chemically induced	6.106226635438361e-15	1.0291946506504979e-13	0.010416666666666668	0.8148056077504143	1	2
disease progression	gastritis/complications	6.106226635438361e-15	1.0291946506504979e-13	0.010416666666666668	0.8148056077504143	1	2
disease progression	enterocolitis/chemically induced	1.5354717497473303e-11	1.744095628789087e-10	0.020833333333333332	0.8148056077504143	1	2
biomarkers/analysis	colitis ulcerative/drug therapy	0.004063911932208342	0.007167574631489817	0.12108062709966406	0.8148056077504143	1	2
biomarkers/analysis	feces/chemistry	9.072875006843617e-09	6.516257307320674e-08	0.001959686450167973	0.5583234571556446	2	2
biomarkers/analysis	antineoplastic agents/adverse effects	0.0012062888693431528	0.002431505540941939	0.03125	0.8148056077504143	1	2
biomarkers/analysis	intestinal mucosa/chemistry	0.0012062888693431528	0.002431505540941939	0.03125	0.8148056077504143	1	2
biomarkers/analysis	leukemia lymphocytic chronic b-cell/drug therapy	0.0012062888693431528	0.002431505540941939	0.03125	0.8148056077504143	1	2
biomarkers/analysis	class i phosphatidylinositol 3-kinases/antagonists & inhibitors	0.0012062888693431528	0.002431505540941939	0.03125	0.8148056077504143	1	2
biomarkers/analysis	purines/adverse effects	0.0012062888693431528	0.002431505540941939	0.03125	0.8148056077504143	1	2
biomarkers/analysis	colon/chemistry	0.0012062888693431528	0.002431505540941939	0.03125	0.8148056077504143	1	2
biomarkers/analysis	lymphocytosis/chemically induced	0.0012062888693431528	0.002431505540941939	0.03125	0.8148056077504143	1	2
biomarkers/analysis	protein kinase inhibitors/adverse effects	0.0012062888693431528	0.002431505540941939	0.03125	0.8148056077504143	1	2
biomarkers/analysis	apoptosis/drug effects	0.0012062888693431528	0.002431505540941939	0.03125	0.8148056077504143	1	2
biomarkers/analysis	quinazolinones/adverse effects	0.0012062888693431528	0.002431505540941939	0.03125	0.8148056077504143	1	2
biomarkers/analysis	lymphoma non-hodgkin/drug therapy	0.0012062888693431528	0.002431505540941939	0.03125	0.8148056077504143	1	2
biomarkers/analysis	PIK3CD	0.0012062888693431528	0.002431505540941939	0.03125	0.8148056077504143	1	2
biomarkers/analysis	diarrhea/diagnosis	7.173081661981939e-08	4.714383859604482e-07	0.03125	0.8148056077504143	1	2
biomarkers/analysis	colitis microscopic/diagnosis	7.173081661981939e-08	4.714383859604482e-07	0.03125	0.8148056077504143	1	2
biomarkers/analysis	leukocyte l1 antigen complex/analysis	9.072875006843617e-09	6.516257307320674e-08	0.001959686450167973	0.5583234571556446	2	2
abdominal pain/chemically induced	gastritis/complications	6.106226635438361e-15	1.0291946506504979e-13	0.010416666666666668	0.8148056077504143	1	2
abdominal pain/chemically induced	enterocolitis/chemically induced	1.5354717497473303e-11	1.744095628789087e-10	0.020833333333333332	0.8148056077504143	1	2
ustekinumab/therapeutic use	colitis ulcerative/drug therapy	4.107825191113079e-15	8.672075403460945e-14	0.041666666666666664	0.8148056077504143	1	2
ustekinumab/therapeutic use	interleukin-23/antagonists & inhibitors	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
ustekinumab/therapeutic use	interleukin-12/antagonists & inhibitors	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
colitis ulcerative/drug therapy	interleukin-23/antagonists & inhibitors	4.107825191113079e-15	8.672075403460945e-14	0.041666666666666664	0.8148056077504143	1	2
colitis ulcerative/drug therapy	feces/chemistry	6.287970144569499e-12	7.383066068623738e-11	0.003891377379619262	0.5583234571556446	2	2
colitis ulcerative/drug therapy	crohn disease/drug therapy	0.0	0.0	0.041666666666666664	0.8148056077504143	1	2
colitis ulcerative/drug therapy	dose-response relationship drug	0.0010812444968840706	0.0022803239137111075	0.12108062709966406	0.8148056077504143	1	2
colitis ulcerative/drug therapy	leukocyte l1 antigen complex/analysis	6.287970144569499e-12	7.383066068623738e-11	0.003891377379619262	0.5583234571556446	2	2
colitis ulcerative/drug therapy	interleukin-12/antagonists & inhibitors	4.107825191113079e-15	8.672075403460945e-14	0.041666666666666664	0.8148056077504143	1	2
colitis ulcerative/drug therapy	diarrhea/etiology	3.338813736597501e-08	2.2510066804802509e-07	0.041666666666666664	0.8148056077504143	1	2
colitis ulcerative/drug therapy	gastrointestinal hemorrhage/etiology	3.338813736597501e-08	2.2510066804802509e-07	0.041666666666666664	0.8148056077504143	1	2
colitis ulcerative/drug therapy	prednisolone/administration & dosage	3.338813736597501e-08	2.2510066804802509e-07	0.041666666666666664	0.8148056077504143	1	2
colitis ulcerative/drug therapy	glucocorticoids/administration & dosage	3.338813736597501e-08	2.2510066804802509e-07	0.041666666666666664	0.8148056077504143	1	2
colitis ulcerative/drug therapy	diarrhea/diagnosis	1.621400791407268e-10	1.5777265995400858e-09	0.041666666666666664	0.8148056077504143	1	2
colitis ulcerative/drug therapy	abdominal pain/etiology	3.338813736597501e-08	2.2510066804802509e-07	0.041666666666666664	0.8148056077504143	1	2
colitis ulcerative/drug therapy	colitis microscopic/diagnosis	1.621400791407268e-10	1.5777265995400858e-09	0.041666666666666664	0.8148056077504143	1	2
antineoplastic agents/adverse effects	intestinal mucosa/chemistry	1.4335762558159715e-05	4.832539313960291e-05	0.010416666666666668	0.8148056077504143	1	2
antineoplastic agents/adverse effects	leukemia lymphocytic chronic b-cell/drug therapy	1.4335762558159715e-05	4.832539313960291e-05	0.010416666666666668	0.8148056077504143	1	2
antineoplastic agents/adverse effects	class i phosphatidylinositol 3-kinases/antagonists & inhibitors	1.4335762558159715e-05	4.832539313960291e-05	0.010416666666666668	0.8148056077504143	1	2
antineoplastic agents/adverse effects	purines/adverse effects	1.4335762558159715e-05	4.832539313960291e-05	0.010416666666666668	0.8148056077504143	1	2
antineoplastic agents/adverse effects	colon/chemistry	1.4335762558159715e-05	4.832539313960291e-05	0.010416666666666668	0.8148056077504143	1	2
antineoplastic agents/adverse effects	lymphocytosis/chemically induced	1.4335762558159715e-05	4.832539313960291e-05	0.010416666666666668	0.8148056077504143	1	2
antineoplastic agents/adverse effects	protein kinase inhibitors/adverse effects	1.4335762558159715e-05	4.832539313960291e-05	0.010416666666666668	0.8148056077504143	1	2
antineoplastic agents/adverse effects	apoptosis/drug effects	1.4335762558159715e-05	4.832539313960291e-05	0.010416666666666668	0.8148056077504143	1	2
antineoplastic agents/adverse effects	quinazolinones/adverse effects	1.4335762558159715e-05	4.832539313960291e-05	0.010416666666666668	0.8148056077504143	1	2
antineoplastic agents/adverse effects	lymphoma non-hodgkin/drug therapy	1.4335762558159715e-05	4.832539313960291e-05	0.010416666666666668	0.8148056077504143	1	2
antineoplastic agents/adverse effects	PIK3CD	1.4335762558159715e-05	4.832539313960291e-05	0.010416666666666668	0.8148056077504143	1	2
intestinal mucosa/chemistry	leukemia lymphocytic chronic b-cell/drug therapy	1.4335762558159715e-05	4.832539313960291e-05	0.010416666666666668	0.8148056077504143	1	2
intestinal mucosa/chemistry	class i phosphatidylinositol 3-kinases/antagonists & inhibitors	1.4335762558159715e-05	4.832539313960291e-05	0.010416666666666668	0.8148056077504143	1	2
intestinal mucosa/chemistry	purines/adverse effects	1.4335762558159715e-05	4.832539313960291e-05	0.010416666666666668	0.8148056077504143	1	2
intestinal mucosa/chemistry	colon/chemistry	1.4335762558159715e-05	4.832539313960291e-05	0.010416666666666668	0.8148056077504143	1	2
intestinal mucosa/chemistry	lymphocytosis/chemically induced	1.4335762558159715e-05	4.832539313960291e-05	0.010416666666666668	0.8148056077504143	1	2
intestinal mucosa/chemistry	protein kinase inhibitors/adverse effects	1.4335762558159715e-05	4.832539313960291e-05	0.010416666666666668	0.8148056077504143	1	2
intestinal mucosa/chemistry	apoptosis/drug effects	1.4335762558159715e-05	4.832539313960291e-05	0.010416666666666668	0.8148056077504143	1	2
intestinal mucosa/chemistry	quinazolinones/adverse effects	1.4335762558159715e-05	4.832539313960291e-05	0.010416666666666668	0.8148056077504143	1	2
intestinal mucosa/chemistry	lymphoma non-hodgkin/drug therapy	1.4335762558159715e-05	4.832539313960291e-05	0.010416666666666668	0.8148056077504143	1	2
intestinal mucosa/chemistry	PIK3CD	1.4335762558159715e-05	4.832539313960291e-05	0.010416666666666668	0.8148056077504143	1	2
leukemia lymphocytic chronic b-cell/drug therapy	class i phosphatidylinositol 3-kinases/antagonists & inhibitors	1.4335762558159715e-05	4.832539313960291e-05	0.010416666666666668	0.8148056077504143	1	2
leukemia lymphocytic chronic b-cell/drug therapy	purines/adverse effects	1.4335762558159715e-05	4.832539313960291e-05	0.010416666666666668	0.8148056077504143	1	2
leukemia lymphocytic chronic b-cell/drug therapy	colon/chemistry	1.4335762558159715e-05	4.832539313960291e-05	0.010416666666666668	0.8148056077504143	1	2
leukemia lymphocytic chronic b-cell/drug therapy	lymphocytosis/chemically induced	1.4335762558159715e-05	4.832539313960291e-05	0.010416666666666668	0.8148056077504143	1	2
leukemia lymphocytic chronic b-cell/drug therapy	protein kinase inhibitors/adverse effects	1.4335762558159715e-05	4.832539313960291e-05	0.010416666666666668	0.8148056077504143	1	2
leukemia lymphocytic chronic b-cell/drug therapy	apoptosis/drug effects	1.4335762558159715e-05	4.832539313960291e-05	0.010416666666666668	0.8148056077504143	1	2
leukemia lymphocytic chronic b-cell/drug therapy	quinazolinones/adverse effects	1.4335762558159715e-05	4.832539313960291e-05	0.010416666666666668	0.8148056077504143	1	2
leukemia lymphocytic chronic b-cell/drug therapy	lymphoma non-hodgkin/drug therapy	1.4335762558159715e-05	4.832539313960291e-05	0.010416666666666668	0.8148056077504143	1	2
leukemia lymphocytic chronic b-cell/drug therapy	PIK3CD	1.4335762558159715e-05	4.832539313960291e-05	0.010416666666666668	0.8148056077504143	1	2
class i phosphatidylinositol 3-kinases/antagonists & inhibitors	purines/adverse effects	1.4335762558159715e-05	4.832539313960291e-05	0.010416666666666668	0.8148056077504143	1	2
class i phosphatidylinositol 3-kinases/antagonists & inhibitors	colon/chemistry	1.4335762558159715e-05	4.832539313960291e-05	0.010416666666666668	0.8148056077504143	1	2
class i phosphatidylinositol 3-kinases/antagonists & inhibitors	lymphocytosis/chemically induced	1.4335762558159715e-05	4.832539313960291e-05	0.010416666666666668	0.8148056077504143	1	2
class i phosphatidylinositol 3-kinases/antagonists & inhibitors	protein kinase inhibitors/adverse effects	1.4335762558159715e-05	4.832539313960291e-05	0.010416666666666668	0.8148056077504143	1	2
class i phosphatidylinositol 3-kinases/antagonists & inhibitors	apoptosis/drug effects	1.4335762558159715e-05	4.832539313960291e-05	0.010416666666666668	0.8148056077504143	1	2
class i phosphatidylinositol 3-kinases/antagonists & inhibitors	quinazolinones/adverse effects	1.4335762558159715e-05	4.832539313960291e-05	0.010416666666666668	0.8148056077504143	1	2
class i phosphatidylinositol 3-kinases/antagonists & inhibitors	lymphoma non-hodgkin/drug therapy	1.4335762558159715e-05	4.832539313960291e-05	0.010416666666666668	0.8148056077504143	1	2
class i phosphatidylinositol 3-kinases/antagonists & inhibitors	PIK3CD	1.4335762558159715e-05	4.832539313960291e-05	0.010416666666666668	0.8148056077504143	1	2
purines/adverse effects	colon/chemistry	1.4335762558159715e-05	4.832539313960291e-05	0.010416666666666668	0.8148056077504143	1	2
purines/adverse effects	lymphocytosis/chemically induced	1.4335762558159715e-05	4.832539313960291e-05	0.010416666666666668	0.8148056077504143	1	2
purines/adverse effects	protein kinase inhibitors/adverse effects	1.4335762558159715e-05	4.832539313960291e-05	0.010416666666666668	0.8148056077504143	1	2
purines/adverse effects	apoptosis/drug effects	1.4335762558159715e-05	4.832539313960291e-05	0.010416666666666668	0.8148056077504143	1	2
purines/adverse effects	quinazolinones/adverse effects	1.4335762558159715e-05	4.832539313960291e-05	0.010416666666666668	0.8148056077504143	1	2
purines/adverse effects	lymphoma non-hodgkin/drug therapy	1.4335762558159715e-05	4.832539313960291e-05	0.010416666666666668	0.8148056077504143	1	2
purines/adverse effects	PIK3CD	1.4335762558159715e-05	4.832539313960291e-05	0.010416666666666668	0.8148056077504143	1	2
colon/chemistry	lymphocytosis/chemically induced	1.4335762558159715e-05	4.832539313960291e-05	0.010416666666666668	0.8148056077504143	1	2
colon/chemistry	protein kinase inhibitors/adverse effects	1.4335762558159715e-05	4.832539313960291e-05	0.010416666666666668	0.8148056077504143	1	2
colon/chemistry	apoptosis/drug effects	1.4335762558159715e-05	4.832539313960291e-05	0.010416666666666668	0.8148056077504143	1	2
colon/chemistry	quinazolinones/adverse effects	1.4335762558159715e-05	4.832539313960291e-05	0.010416666666666668	0.8148056077504143	1	2
colon/chemistry	lymphoma non-hodgkin/drug therapy	1.4335762558159715e-05	4.832539313960291e-05	0.010416666666666668	0.8148056077504143	1	2
colon/chemistry	PIK3CD	1.4335762558159715e-05	4.832539313960291e-05	0.010416666666666668	0.8148056077504143	1	2
lymphocytosis/chemically induced	protein kinase inhibitors/adverse effects	1.4335762558159715e-05	4.832539313960291e-05	0.010416666666666668	0.8148056077504143	1	2
lymphocytosis/chemically induced	apoptosis/drug effects	1.4335762558159715e-05	4.832539313960291e-05	0.010416666666666668	0.8148056077504143	1	2
lymphocytosis/chemically induced	quinazolinones/adverse effects	1.4335762558159715e-05	4.832539313960291e-05	0.010416666666666668	0.8148056077504143	1	2
lymphocytosis/chemically induced	lymphoma non-hodgkin/drug therapy	1.4335762558159715e-05	4.832539313960291e-05	0.010416666666666668	0.8148056077504143	1	2
lymphocytosis/chemically induced	PIK3CD	1.4335762558159715e-05	4.832539313960291e-05	0.010416666666666668	0.8148056077504143	1	2
protein kinase inhibitors/adverse effects	apoptosis/drug effects	1.4335762558159715e-05	4.832539313960291e-05	0.010416666666666668	0.8148056077504143	1	2
protein kinase inhibitors/adverse effects	quinazolinones/adverse effects	1.4335762558159715e-05	4.832539313960291e-05	0.010416666666666668	0.8148056077504143	1	2
protein kinase inhibitors/adverse effects	lymphoma non-hodgkin/drug therapy	1.4335762558159715e-05	4.832539313960291e-05	0.010416666666666668	0.8148056077504143	1	2
protein kinase inhibitors/adverse effects	PIK3CD	1.4335762558159715e-05	4.832539313960291e-05	0.010416666666666668	0.8148056077504143	1	2
apoptosis/drug effects	quinazolinones/adverse effects	1.4335762558159715e-05	4.832539313960291e-05	0.010416666666666668	0.8148056077504143	1	2
apoptosis/drug effects	lymphoma non-hodgkin/drug therapy	1.4335762558159715e-05	4.832539313960291e-05	0.010416666666666668	0.8148056077504143	1	2
apoptosis/drug effects	PIK3CD	1.4335762558159715e-05	4.832539313960291e-05	0.010416666666666668	0.8148056077504143	1	2
quinazolinones/adverse effects	lymphoma non-hodgkin/drug therapy	1.4335762558159715e-05	4.832539313960291e-05	0.010416666666666668	0.8148056077504143	1	2
quinazolinones/adverse effects	PIK3CD	1.4335762558159715e-05	4.832539313960291e-05	0.010416666666666668	0.8148056077504143	1	2
lymphoma non-hodgkin/drug therapy	PIK3CD	1.4335762558159715e-05	4.832539313960291e-05	0.010416666666666668	0.8148056077504143	1	2
MIR15B	NRF1	4.611765902828857e-05	0.00012903066582211928	0.010416666666666668	0.8148056077504143	1	2
gastritis/complications	enterocolitis/chemically induced	1.5354717497473303e-11	1.744095628789087e-10	0.020833333333333332	0.8148056077504143	1	2
enterocolitis/chemically induced	colitis ulcerative/physiopathology	0.0	0.0	0.020833333333333332	0.8148056077504143	1	2
enterocolitis/chemically induced	crohn disease/physiopathology	0.0	0.0	0.020833333333333332	0.8148056077504143	1	2
interleukin-23/antagonists & inhibitors	interleukin-12/antagonists & inhibitors	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
colitis/therapy	immunologic factors	0.0	0.0	0.020833333333333332	0.8148056077504143	1	2
colitis/diagnosis	postoperative complications	0.0	0.0	0.020833333333333336	0.8148056077504143	1	2
colitis/diagnosis	gastrointestinal tract/metabolism	1.2212453270876722e-15	2.6587528475137862e-14	0.020833333333333336	0.8148056077504143	1	2
colitis/diagnosis	b7-h1 antigen/metabolism	1.2212453270876722e-15	2.6587528475137862e-14	0.020833333333333336	0.8148056077504143	1	2
colitis/diagnosis	programmed cell death 1 receptor/metabolism	1.2212453270876722e-15	2.6587528475137862e-14	0.020833333333333332	0.8148056077504143	1	2
colitis/diagnosis	disease susceptibility	0.0	0.0	0.020833333333333336	0.8148056077504143	1	2
escherichia coli infections/drug therapy	virus diseases/etiology	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
escherichia coli infections/drug therapy	clostridium infections/chemically induced	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
escherichia coli infections/drug therapy	anti-bacterial agents/adverse effects	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
virus diseases/etiology	clostridium infections/chemically induced	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
virus diseases/etiology	anti-bacterial agents/adverse effects	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
protein kinase inhibitors/therapeutic use	ipilimumab/adverse effects	4.328700447031597e-05	0.00012903066582211928	0.09375000000000001	0.8148056077504143	1	2
ipilimumab/adverse effects	drug-related side effects and adverse reactions/diagnosis	9.471766291735406e-06	3.632292027472844e-05	0.09375000000000001	0.8148056077504143	1	2
tryptophan/pharmacology	AHR	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
clostridium infections/chemically induced	anti-bacterial agents/adverse effects	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
disease susceptibility	postoperative complications	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
inflammatory bowel diseases/complications	colitis microscopic/chemically induced	0.0	0.0	0.041447368421052636	0.8148056077504143	1	2
myasthenia gravis/diagnosis	immunosuppressive agents/therapeutic use	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
myasthenia gravis/diagnosis	skin neoplasms/immunology	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
myasthenia gravis/diagnosis	melanoma/immunology	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
myasthenia gravis/diagnosis	immunocompromised host	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
myasthenia gravis/diagnosis	prednisone/therapeutic use	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
myasthenia gravis/diagnosis	antibodies monoclonal humanized/adverse effects	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
immunosuppressive agents/therapeutic use	skin neoplasms/immunology	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
immunosuppressive agents/therapeutic use	antibodies monoclonal humanized/adverse effects	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
immunosuppressive agents/therapeutic use	melanoma/immunology	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
immunosuppressive agents/therapeutic use	immunocompromised host	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
immunosuppressive agents/therapeutic use	prednisone/therapeutic use	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
steroids/therapeutic use	feces	0.0	0.0	0.020833333333333332	0.8148056077504143	1	2
steroids/therapeutic use	lung neoplasms	0.0	0.0	0.020833333333333332	0.8148056077504143	1	2
steroids/therapeutic use	dose-response relationship drug	1.439032364380921e-07	9.08633728566805e-07	0.06184210526315789	0.8148056077504143	1	2
inflammation	gentian violet	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
prednisone/therapeutic use	antibodies monoclonal humanized/adverse effects	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
prednisone/therapeutic use	skin neoplasms/immunology	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
prednisone/therapeutic use	melanoma/immunology	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
prednisone/therapeutic use	immunocompromised host	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
gastrointestinal tract/metabolism	programmed cell death 1 receptor/metabolism	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
gastrointestinal tract/metabolism	b7-h1 antigen/metabolism	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
b7-h1 antigen/metabolism	programmed cell death 1 receptor/metabolism	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
skin neoplasms/immunology	antibodies monoclonal humanized/adverse effects	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
skin neoplasms/immunology	melanoma/immunology	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
skin neoplasms/immunology	immunocompromised host	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
melanoma/immunology	antibodies monoclonal humanized/adverse effects	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
melanoma/immunology	immunocompromised host	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
immunocompromised host	antibodies monoclonal humanized/adverse effects	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
antibodies monoclonal humanized/administration & dosage	dose-response relationship drug	7.336218259546001e-07	4.1778463657905015e-06	0.03125	0.8148056077504143	1	2
antibodies monoclonal humanized/administration & dosage	drugs investigational/administration & dosage	6.106226635438361e-15	1.0291946506504979e-13	0.010416666666666668	0.8148056077504143	1	2
antibodies monoclonal humanized/administration & dosage	neoplasms/diagnosis	6.106226635438361e-15	1.0291946506504979e-13	0.010416666666666668	0.8148056077504143	1	2
dose-response relationship drug	neoplasms/diagnosis	7.336218259546001e-07	4.1778463657905015e-06	0.03125	0.8148056077504143	1	2
dose-response relationship drug	feces	2.3560930983990147e-11	2.633280521740075e-10	0.03125	0.8148056077504143	1	2
dose-response relationship drug	feces/chemistry	0.0010812444968840706	0.0022803239137111075	0.09178331466965287	0.8148056077504143	1	2
dose-response relationship drug	leukocyte l1 antigen complex/analysis	0.0010812444968840706	0.0022803239137111075	0.09178331466965287	0.8148056077504143	1	2
dose-response relationship drug	drugs investigational/administration & dosage	7.336218259546001e-07	4.1778463657905015e-06	0.03125	0.8148056077504143	1	2
dose-response relationship drug	diarrhea/etiology	1.439032364380921e-07	9.08633728566805e-07	0.03125	0.8148056077504143	1	2
dose-response relationship drug	gastrointestinal hemorrhage/etiology	1.439032364380921e-07	9.08633728566805e-07	0.03125	0.8148056077504143	1	2
dose-response relationship drug	prednisolone/administration & dosage	1.439032364380921e-07	9.08633728566805e-07	0.03125	0.8148056077504143	1	2
dose-response relationship drug	glucocorticoids/administration & dosage	1.439032364380921e-07	9.08633728566805e-07	0.03125	0.8148056077504143	1	2
dose-response relationship drug	abdominal pain/etiology	1.439032364380921e-07	9.08633728566805e-07	0.03125	0.8148056077504143	1	2
drugs investigational/administration & dosage	neoplasms/diagnosis	6.106226635438361e-15	1.0291946506504979e-13	0.010416666666666668	0.8148056077504143	1	2
colitis collagenous/drug therapy	skin neoplasms/complications	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
glycoproteins/metabolism	b7-h1 antigen/antagonists & inhibitors	1.621400791407268e-10	1.5777265995400858e-09	0.03125	0.8148056077504143	1	2
glycoproteins/metabolism	biomarkers/metabolism	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
glycoproteins/metabolism	adenocarcinoma of lung/drug therapy	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
b7-h1 antigen/antagonists & inhibitors	colitis/epidemiology	1.621400791407268e-10	1.5777265995400858e-09	0.03125	0.8148056077504143	1	2
b7-h1 antigen/antagonists & inhibitors	biomarkers/metabolism	1.621400791407268e-10	1.5777265995400858e-09	0.03125	0.8148056077504143	1	2
b7-h1 antigen/antagonists & inhibitors	adenocarcinoma of lung/drug therapy	1.621400791407268e-10	1.5777265995400858e-09	0.03125	0.8148056077504143	1	2
neoplasm recurrence local/drug therapy	endometrial neoplasms/drug therapy	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
neoplasm recurrence local/drug therapy	antibodies monoclonal humanized	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
biomarkers/metabolism	adenocarcinoma of lung/drug therapy	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
feces/chemistry	leukocyte l1 antigen complex/analysis	0.0	0.0	6.998880179171334e-06	0.32151609391373515	3	2
feces/chemistry	diarrhea/etiology	3.338813736597501e-08	2.2510066804802509e-07	0.03125	0.8148056077504143	1	2
feces/chemistry	gastrointestinal hemorrhage/etiology	3.338813736597501e-08	2.2510066804802509e-07	0.03125	0.8148056077504143	1	2
feces/chemistry	prednisolone/administration & dosage	3.338813736597501e-08	2.2510066804802509e-07	0.03125	0.8148056077504143	1	2
feces/chemistry	glucocorticoids/administration & dosage	3.338813736597501e-08	2.2510066804802509e-07	0.03125	0.8148056077504143	1	2
feces/chemistry	diarrhea/diagnosis	1.621400791407268e-10	1.5777265995400858e-09	0.03125	0.8148056077504143	1	2
feces/chemistry	abdominal pain/etiology	3.338813736597501e-08	2.2510066804802509e-07	0.03125	0.8148056077504143	1	2
feces/chemistry	colitis microscopic/diagnosis	1.621400791407268e-10	1.5777265995400858e-09	0.03125	0.8148056077504143	1	2
leukocyte l1 antigen complex/analysis	diarrhea/etiology	3.338813736597501e-08	2.2510066804802509e-07	0.03125	0.8148056077504143	1	2
leukocyte l1 antigen complex/analysis	gastrointestinal hemorrhage/etiology	3.338813736597501e-08	2.2510066804802509e-07	0.03125	0.8148056077504143	1	2
leukocyte l1 antigen complex/analysis	prednisolone/administration & dosage	3.338813736597501e-08	2.2510066804802509e-07	0.03125	0.8148056077504143	1	2
leukocyte l1 antigen complex/analysis	glucocorticoids/administration & dosage	3.338813736597501e-08	2.2510066804802509e-07	0.03125	0.8148056077504143	1	2
leukocyte l1 antigen complex/analysis	diarrhea/diagnosis	1.621400791407268e-10	1.5777265995400858e-09	0.03125	0.8148056077504143	1	2
leukocyte l1 antigen complex/analysis	abdominal pain/etiology	3.338813736597501e-08	2.2510066804802509e-07	0.03125	0.8148056077504143	1	2
leukocyte l1 antigen complex/analysis	colitis microscopic/diagnosis	1.621400791407268e-10	1.5777265995400858e-09	0.03125	0.8148056077504143	1	2
endometrial neoplasms/drug therapy	antibodies monoclonal humanized	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
diarrhea/etiology	gastrointestinal hemorrhage/etiology	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
diarrhea/etiology	prednisolone/administration & dosage	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
diarrhea/etiology	glucocorticoids/administration & dosage	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
diarrhea/etiology	abdominal pain/etiology	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
gastrointestinal hemorrhage/etiology	prednisolone/administration & dosage	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
gastrointestinal hemorrhage/etiology	glucocorticoids/administration & dosage	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
gastrointestinal hemorrhage/etiology	abdominal pain/etiology	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
prednisolone/administration & dosage	glucocorticoids/administration & dosage	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
prednisolone/administration & dosage	abdominal pain/etiology	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
glucocorticoids/administration & dosage	abdominal pain/etiology	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
diarrhea/diagnosis	colitis microscopic/diagnosis	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
diarrhea/therapy	neoplasms/therapy	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
colitis ulcerative/physiopathology	crohn disease/physiopathology	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
antibodies monoclonal humanized/therapeutic use	steroids/adverse effects	0.0	0.0	0.010416666666666668	0.8148056077504143	1	2
lymphocytes/drug effects	vitamin d/administration & dosage	1.932526361159148e-10	1.5777265995400858e-09	0.010416666666666668	0.8148056077504143	1	2
lymphocytes/drug effects	neutrophils/drug effects	1.932526361159148e-10	1.5777265995400858e-09	0.010416666666666668	0.8148056077504143	1	2
lymphocytes/drug effects	antibodies monoclonal/adverse effects	1.932526361159148e-10	1.5777265995400858e-09	0.010416666666666668	0.8148056077504143	1	2
vitamin d/administration & dosage	neutrophils/drug effects	1.932526361159148e-10	1.5777265995400858e-09	0.010416666666666668	0.8148056077504143	1	2
vitamin d/administration & dosage	antibodies monoclonal/adverse effects	1.932526361159148e-10	1.5777265995400858e-09	0.010416666666666668	0.8148056077504143	1	2
intestinal mucosa/immunology	colon/immunology	0.0	0.0	0.020833333333333332	0.8148056077504143	1	2
colon/immunology	t-lymphocyte subsets/immunology	0.0	0.0	0.020833333333333336	0.8148056077504143	1	2
neutrophils/drug effects	antibodies monoclonal/adverse effects	1.932526361159148e-10	1.5777265995400858e-09	0.010416666666666668	0.8148056077504143	1	2
